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Abstract 
SCOTT A. LUJAN:  Bacterial Conjugation and its Inhibition: The Hows and 
Whys of Conjugation and What Can be Done to Control It 
(Under the direction of Matthew R. Redinbo, Ph.D.) 
 
Conjugation is the primary vehicle for the horizontal transfer virulence factor 
genes, such as antibiotic resistance, within and between bacterial strains. In 
certain epicenters, such as hospitals in less developed parts of the world, 
immune-compromised patients and misuse of antibiotics combine to select for 
the development and dissemination of these pathogenicity factors via 
conjugation. Inhibition of conjugation would prove a boon for curbing the creation 
and spread of new virulent or multi-drug resistant strains. DNA relaxases are the 
keystone proteins of each conjugative system. TraI is the relaxase of the F 
plasmid, the archetypal model system for conjugation. Toward revelation and 
inhibition of relaxase mechanisms, I used bioinformatics and limited proteolysis 
to find and identify new domains on the F TraI enzyme. I then solved TraI/DNA 
co-crystal structures that showed a novel DNA binding mode. Based on structure 
comparisons, sequence conservation, and mutant activity studies, I proposed a 
mechanism for TraI activity that required the existence of a dual phosphotyrosine 
intermediate, which has since been observed. I then demonstrated that 
bisphosphonate compounds mimicking this intermediate are nanomolar in vitro 
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TraI inhibitors. I determined the relaxase structure in complex with one such 
inhibitor, bound as predicted. We showed that several of these compounds are 
potent in cell inhibitors of conjugation that often selectively kill conjugation-
capable cells, a novel antibiotic paradigm. We showed that oral treatment of 
gnotobiotic mice with two inhibitors, clodronate and etidronate, decreased the 
gastrointestinal F+ bacterial load twentyfold without apparent side effects. Beyond 
the model system, etidronate showed selective in cell potency versus cells 
harboring a known clinical resistance-bearing R100 plasmid. Etidronate and 
clodronate are already clinically approved for the treatment of bone loss in 
humans. Toward more general relaxase inhibition phylogenetic analyses and 
studies with other medically relevant relaxases, including viral replicative 
relaxases, are ongoing. 
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1 Background and Significance 
In many underdeveloped areas around the globe, antibiotic resistance 
among virulent bacterial strains is reaching crisis proportions. Bacterial 
conjugation is a major player in the spread of antibiotic resistance within and 
between bacterial strains. The F-plasmid conjugation system is used as a model 
system for general bacterial conjugation. TraI, also known as DNA Helicase I, is 
a keystone protein for F-plasmid conjugation: it possesses both helicase and 
relaxase activities necessary for the plasmid mobilization phase of conjugation 
(1). Transfer assays show that certain TraI truncations maintain nicking and 
unwinding activity but abrogate strand transfer (1). This suggests that TraI plays 
a crucial role beyond the mobilization phase. The mechanisms of TraI activity are 
not well understood, nor are its extended roles. F TraI relaxase mechanisms 
have been postulated based on the functions of TraI homologues, including TrwC 
of the R388 IncW plasmid and TraI of the RP4 IncP plasmid. However, 
architectural and biochemical data suggest that F TraI relaxase mechanisms vary 
somewhat from those of TrwC and a great deal from those of RP4 TraI (2, 3). 
Computational studies now suggest structural reasons for this difference and 
illustrate the relationship between structural details and related mechanisms.  My 
2 
work will test these suggestions and reveal the structural basis for TraI function 
as a model for R-plasmid relaxase/helicases.  
1.1 Humanity at War 
Horizontal transfer of genetic information among bacteria is accomplished 
mainly through conjugation (4, 5). It is usually mediated by a conjugative plasmid 
residing in the cytoplasm or integrated into the genomic DNA of the donor cell. 
There is an energy cost associated with hosting a plasmid: plasmid repair, 
translation of plasmid proteins, and copy number maintenance all use valuable 
cellular resources. As with laboratory strains transformed with artificial vectors, 
daughter cells that lack foreign plasmids are at a selective advantage versus 
those that are hosts. This helps curb the spread of plasmid borne antibiotic 
resistance and virulence factors. Problems arise when a bacterial population, 
some individuals of which are plasmid hosts, is subjected to selective pressure, 
such as antibiotic treatments. The selective balance then shifts to daughter cells 
that inherit plasmid copies. This in itself is not a major concern for healthcare 
providers, as the modern suite of antibiotics allows some flexibility in 
circumventing resistance. However, continued selective pressure eventually 
encourages the development of new forms of resistance, which can then be 
disseminated via conjugative plasmids (4, 6). It is then probable that some 
bacteria will gain multiple forms of resistance, sometimes to entire classes of 
drugs (4). These multi-drug resistant (MDR) strains can become flexible enough 
to thwart antibiotic treatment altogether, becoming so-called “super bugs”. In 
some underdeveloped countries, the situation can result in local health crises, as 
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is the case with MDR strains of mycobacterium tuberculosis in Russia, Peru, 
certain African nations, and parts of China (7, 8). Resistance-bearing conjugative 
plasmids have been found in many of mankind’s historical nemeses, including 
Haemophilus influenzae (bacterial meningitis), Salmonella typhi (typhoid fever), 
Vibrio strains (cholera and its relatives), and Yersenia pestis (plague) (6). 
Similarly, previously avirulent strains may be pathogenized by the introduction of 
virulence factors via conjugation. Such a process has been implicated by the 
localization of Salmonella typhimurium derived virulence genes on an F-like 
plasmid in pathogenic E. coli O157:H7 and by F-plasmid transfer genes on the 
pFra virulence plasmid of Yersenia pestis strain G8786 (9, 10). Medically, the 
potential benefits of understanding and fighting antibiotic resistance and 
virulence factors spread via conjugative plasmids cannot be overestimated. 
1.2 Conjugation 
Parallels have been drawn between conjugative mobilization and the rolling 
circle form of replication seen in many viruses. Indeed, all of the relaxases 
discussed herein are considered members of the Mob class of nickases, which 
falls (along with the Rep class) into the Rolling Circle Replication  (RCR) 
superfamily of magnesium dependent nucleases (11). Though any true 
evolutionary linkage is unclear, conjugative plasmids, like viruses, are subject to 
selective pressure. Thus, many conjugative systems include genes that provide 
selective advantages to host cells. In E. coli, the R series of plasmids is 
particularly noteworthy for containing and transferring genes that confer antibiotic 
resistance on their hosts (4, 12, 13). Conjugative plasmids are often classified 
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into incompatibility groups, such as IncF for F-plasmid and R100, IncP for RP4 
and RK2, IncW for R388, and Ti-type IncN for R46 (6). Most R plasmids also 
code for a repressor that limits their conjugation rate. The F-plasmid is similar to 
the rest of the R series - nearly identical to plasmid R100 - with the notable 
exception that the repressor gene of F lacks a start codon (14). F may thus be 
considered a constitutively active R100 mutant. As such, I will often refer to F 
and R systems interchangeably. Wild type F also lacks resistance or virulence, a 
rare example of a system that persists on efficiency alone, a true parasite 
conferring no selective advantage to its hosts. F-plasmid must thus rely solely 
upon its conjugation proficiency to propagate successfully. Among the most well 
characterized of all bacterial conjugation systems, The F-plasmid system is an 
ideal model system. My long term goal was to characterize the mechanism of 
plasmid to identify methods to inhibit the propagation of antibiotic 
resistance and bacterial virulence factors.  
There are four major phases in bacterial conjugation (Figure 1):  
1. Contact: a physical connection is made between the donor and recipient 
cells, often through sex pili. The connection must span the cellular 
membranes and cell walls of both cells in order to create a conduit between 
opposing cytoplasmic spaces (12). 
2. Mobilization: the conjugative plasmid is prepared for transfer. The plasmid is 
nicked and separated into component strands, which requires unwinding of 
the duplex DNA. Mobilization results in a single-stranded circular non-transfer 
strand and either a linear or circular single-stranded transfer strand (12). 
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3. Transfer: one linear strand is moved to the cellular membrane and passed 
into the intercellular conduit. Some systems include a “pilot” protein that 
guides the strand through the conduit to the recipient cytoplasm (15, 16). 
4. Replication: the transferred strand is replicated and either re-circularized or 
integrated into the recipient genome. The non-transferred strand is also 
replicated, possibly in conjunction with Step 2 unwinding (12). 
Specific protein systems are involved in each phase of conjugation, usually 
in the form of large, dynamic complexes. Pilus proteins initiate contact with the 
recipient cell and may help conduct the transferred strand across intercellular 
space. Adapter proteins are important for strand transfer, forming the link 
between extracellular pilus assemblies and the cytoplasm of the donor cell (12). 
Mobilization is conducted by a complex dubbed the relaxosome. The relaxosome 
is responsible for the initiation, execution, and termination of strand transfer. In 
the F-plasmid, the relaxosome is composed of three essential proteins (TraI, 
TraY, IHF) and a fourth (TraM) required for maximal activity (17-19).  
1.3 TraI: Keystone of F Plasmid Conjugation 
TraI, also known as DNA Helicase I, possesses both relaxase 
(transesterase) and helicase activities. TraI performs the initial nick that begins 
plasmid transfer, unwinds and separates the nucleotide strands, and has other 
proposed activities during both the mobilization and transfer phases of 
conjugation (20). This makes TraI a key protein in F-plasmid conjugation and 
thus essential to an understanding of conjugation as a whole. 
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1.4 All in the Family: The Relaxase Domain 
The details of the diverse Mob family relaxase mechanisms are poorly 
understood. Multiple sequence alignments show that some 
relaxase/transesterase/nickases possess one catalytic tyrosine residue (TraA 
and VirD2 of Rhizobia and Agrobacteria pTi plasmids; TraI of plasmid RP4 IncQ) 
while other have a constellation of conserved tyrosines (TraA of Corynebacteria 
plasmids; TrwC of plasmid R388 IncW; TraI of plasmid R100 IncF plasmids). The 
IncF/W constellation of two tyrosine pairs follows a pattern of Yy-X3-26-YY, where 
‘y’ denotes either a tyrosine or a  phenylalanine in some IncW relaxases (21). 
(Fig. 2) The tyrosine pairs are thought to be responsible for alternating 
transesterifications during sequential initiations/terminations of the mobilization 
phase in a rolling-circle manner as described for bacteriophage phi X174 (11, 12, 
22). During the nicking (transesterification) reaction, a catalytic tyrosine forms a 
covalent bond with a phosphate of the nicked strand (1, 13). It has been 
postulated that R388 TrwC exploits this covalent bond and acts a pilot protein 
that guides the transferred strand from donor to recipient (12, 15). This was 
suggested through analogy with known pilot proteins of Agrobacterium (Ti-
system) and RP4 TraI (RP4). However, experimental evidence is against an F-
plasmid pilot, and at 1756 residues in length and 191 kDa in mass, TraI is far 
larger than known pilot proteins, an unlikely candidate for transmembrane 
secretion (15, 16). Mutant data with R388 TrwC show that all four tyrosines show 
varying degrees of capability for creating the initial nick (3). The exact reason for 
conserving redundant catalytic residues is unclear.  
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Mechanisms for TraI relaxase activity have been posited in analogy with R388 
TrwC, for which an abundance of mutant activity data exist (3). More recent 
mutational data on TraI activity appear to contradict many of the TrwC results, 
suggesting that either the mechanisms differ or that a much more complicated 
story is in the offing (2). Crystallographic data exist for apo TraI (23) and DNA 
bound TrwC (24), but both structures leave much to be desired. The TraI 
structure lacks the thirty residues of the DNA binding loop (disordered), and the 
TrwC structures lack residues and DNA proximal to the active site (disordered 
and not present, respectively).  
1.5 Something New has been Added: The TFG Domain 
The central 600 residues of F TraI (situated between the relaxase and 
helicase domains) and the carboxyl terminal 300 residues have long been a 
mystery. Transfer is lost upon their truncation or deletion, and activity is not 
recovered upon reconstitution of the helicase and relaxase domains (1). These 
regions lack any previously defined domain architecture and there are no 
homologous regions in IncP, Ti, or even the closely related IncW incompatibility 
groups (R388 TrwC consists of a relaxase domain and a helicase domain 
connected by a short linker with no C-terminal extension) (1). I have now shown, 
via computational analyses, that there resides in TraI residues 300 to 600 a 
Rossman fold domain, similar in structure to the GTPase domain of Thermus 
aquaticus Ffh, dubbed the TraI Ffh GTPase-like domain (TFG) (25). This 
seeming incongruity actually fills in an essential gap in the conjugation sequence 
of events. Consider this question: if mobilization occurs in the cytoplasm, how 
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does the transferred strand move to the inner membrane and couple with the 
conjugative secretion system? The answer hinges on an understanding of the 
function of Ffh. 
Ffh is a member of the bacterial Signal Recognition Particle (SRP). The 
SRP is charged with the task of translocating ribosomes to the inner membrane 
upon translation of membrane targeting sequences (26). Ffh has two domains: 
the M domain, in SRP parlance, which recognizes and binds targeting sequences 
and a small SRP RNA; and an N/G domain, consisting of an N-terminal four-helix 
bundle (N) and a C-terminal GTPase subdomain (G). After signal recognition and 
binding, the complex (Ffh, the ribosome, tRNA, nascent polypeptide, Ffh bound 
GTP, and a small SRP RNA) translocates to the inner membrane, where the Ffh 
N/G domain complexes with an adapter protein, FtsY. FtsY also consists of two 
domains: a C-terminal membrane associating domain; and an N-terminal N/G 
domain. The N/G domains interact along a large interface that includes both 
GTPase active sites. After the nascent polypeptide (signal sequence) passes to 
the secretion system (membrane pore), simultaneous GTP hydrolysis occurs, 
mediating Ffh/FtsY dissociation (27, 28).  
The SRP system suggests a novel activity for TraI only if an FtsY-type 
adapter protein exists in the IncF. TraD is an F encoded hexameric membrane 
protein that interacts with TraI, non-specific DNA, and the conjugal secretion 
system. TraD has a short transmembrane portion and a large Rossman type 
domain (with a subset of canonical NTPase sequences), capped by a four-helix 
bundle. Though it has no native NTPase activity, the TraD p-loop (putative active 
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site) faces out into the cytoplasm (based on homology modeling versus R388 
TrwB (29, 30)). This makes TraD an excellent candidate to play FtsY to TraI’s 
Ffh. (Fig. 3). 
1.6 Summary 
My scientific priorities have shifted since my original thesis proposal. A 
crystal structure of the TFG domain would show unequivocally whether or not 
this domain is structurally homologous to the FtsY family of small GTPases (Aim 
2). Likewise, a co-crystal structure of TraI/TraD or TraI/TraD/DNA, would explore 
a novel TraI function in the transfer phase of conjugation (Aim 3). However, these 
aims are left to future work, as work on Aim 1 (below) and the original long-term 
goal of conjugation inhibition proved to be wildly more successful than originally 
anticipated. 
An understanding of bacterial conjugation is essential for humanity’s long 
war with our microbial adversaries. The F-plasmid conjugation system is an ideal 
model for a large family of medically relevant conjugative plasmids. As the 
keystone of the F-plasmid system, structural knowledge of the various domains 
of TraI has been invaluable in the development of weapons in our continued 
fight. 
I originally proposed (Aim 1) to acquire structural data showing the relative 
partial occupancies of the four F TraI tyrosines coordinated to either small 
oligonucleotides or intermediate/transition state analogues in order to shed light 
on the mechanism. I solved the structure of the TraI relaxase domain in complex 
with one DNA nucleotide. Comparison with other another, apoTraI structure (23) 
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and structures of the R388 homologue, TrwC (24), allowed me to propose a 
multi-tyrosine relaxase mechanism (31).  This in turn allowed me to find small 
molecule inhibitors of relaxase activity, which I showed to be potent both in vitro 
and in cell. I then solved the structure of the relaxase domain in complex with 
DNA and one of these inhibitors, bound as predicted. I then showed that some of 
these inhibitors, including two that are already approved for human use to treat 
unrelated conditions, selectively kill donor cells both in vitro and in a gnotobiotic 
mouse gut. Studies with plasmid systems closely related to the F plasmid have 
been promising. Should inhibition prove viable for broad host range plasmids and 
viruses with replicative relaxases, and should human safety and drug potency 
prove acceptable, the implications for human health are profound. 
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1.7 Figure Legends 
Figure 1. Bacterial Conjugation 
In a simplified schematic of bacterial conjugation, the left-hand cell is R+(the 
donor), the right-hand cell is initially R- (the recipient).  
A. Pre- conjugation: the donor has plasmid encoded drug resistance, the 
recipient has genomic drug resistance.  
B. Contact: a conduit forms for DNA transfer; a mating signal prompts 
relaxosome formation on the plasmid.  
C. Mobilization: the plasmid is nicked, unwound, transported to the 
membrane, and replicated.  
D. Transfer: the nicked strand is transported across the conduit and into the 
recipient.  
E. Replication: the conduit is terminated and the transferred strand is either 
circularized (religated) and replicated (as shown) or integrated into the 
recipient genome (not shown).  
F. Expression: Plasmid genes, including those for new antibiotic resistance, 
are expressed in the recipient, now R+. 
 
Figure 2. Relaxase/Nickase Helicases. 
A representative set of proteins containing relaxase and helicase domains. 
Relaxases in which these are not coupled (such as IncP RP4 TraI) are not 
shown. Groups a and b represent the relaxase proteins common to R-class 
12 
bacterial conjugative plasmids from related incompatibility (Inc) groups. Color 
variations within a domain indicate approximate sub-domains.  
A. These F-type proteins have a relaxase domain with four catalytic tyrosines 
(Yx4), a proposed Ffh GTPase-like domain (TFG), and a helicase domain 
with a characteristic DESS Walker B motif.  
B. IncW relaxases have a relaxase domain with three or four catalytic 
tyrosines and a helicase domain with a characteristic DEAX Walker B 
motif.  
C. Ti-type relaxases (involved in bacteria-to-plant conjugation) have a smaller 
helicase domain with an R388-like DEAX Walker B motif. Agrobacterium 
and Rhizobium relaxases have one catalytic tyrosine (IncP-like); 
Corynebacteria bear an IncF-like four-tyrosine motif.  
Figure 3. Models of Proposed TraI/TraD Interaction 
A. TraI and TraD during plasmid mobilization. Hexameric TraD is 
represented in grey. TraI domains colored as in Fig. 2: relaxase red, TGF 
blue, and helicase green. TraI helicase action pumps the nicked DNA 
strand (cyan) through the Type IV Secretion System (T4SS) pore complex 
in the direction of the blue arrow.  
B. A homology model of the TGF/TraD interaction. The TGF domain (cyan) 
is modeled against Ffh. TraD (blue) is modeled against TrwB. Putative 
NTP binding loops are red. On the right, a second monomer in the TraD 
hexamer is shown as a grey silhouette. 
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Figure 1-2 Relaxase/Nickase Helicases 
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Figure 1-3 Models of Proposed TraI/TraD Interaction 
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2 Inhibition of F Plasmid TraI: Structure, Kinetics, & in 
cell assays 
 Conjugative transfer of plasmid DNA via close cell-cell junctions is the 
main route by which antibiotic resistance genes spread between bacterial strains. 
Relaxases are essential for conjugative transfer and act by cleaving DNA strands 
and forming covalent phosphotyrosine linkages. Based on data indicating that 
multi-tyrosine relaxase enzymes can accommodate two phosphotyrosine 
intermediates within their divalent metal-containing active sites, we hypothesized 
that bisphosphonates would inhibit relaxase activity and conjugative DNA 
transfer.  We identified bisphosphonates that are nanomolar in vitro relaxase 
inhibitors.  Furthermore, we utilized cell-based assays to demonstrate that these 
compounds are highly effective at preventing DNA transfer and at selectively 
killing cells harboring conjugative plasmids.  Two potent inhibitors, clodronate 
and etidronate, are already clinically approved to treat bone loss. Thus, the 
inhibition of conjugative relaxases is a potentially novel antimicrobial approach, 
one that selectively targets bacteria capable of transferring antibiotic resistance 
and generating multidrug resistant strains. 
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2.1 Introduction 
Conjugative elements are responsible for the majority of horizontal gene 
transfers within and between bacterial strains (reviewed (1)), as first described 
for the Escherichia coli F plasmid by Lederberg and Tatum in 1946 (2). 
Conjugative DNA transfer is also the central mechanism by which antibiotic 
resistance and virulence factors are propagated in bacterial populations 
(reviewed (3)). Indeed, it is well established that antibiotic resistance can be 
rapidly acquired in clinical settings, and that such acquisition is critically 
dependent on conjugative DNA transfer (reviewed (4)).  Small molecule inhibition 
of conjugation could prove to be a powerful method for curbing the generation 
and spread of multi-drug resistant strains. Past studies suggested that various 
antibiotics, polycyclic chemicals, and crude extracts inhibit conjugation at 
concentrations less than the antibacterial minimum inhibitory concentration 
(MIC)(5-11); however, most of these effects have been attributed to non-
conjugation-specific inhibition of bacterial growth or DNA synthesis(12-15). This 
study describes a bottom-up approach used to identify the first small molecule 
inhibitors of conjugative DNA transfer that target an enzyme of the conjugative 
system. 
 
The DNA relaxase is a central enzyme in each conjugative system (16-
18), and thus is a prime target for inhibition. The conjugative relaxase initiates 
DNA transfer with a site and strand specific single-stranded DNA (ssDNA) nick in 
the transferred strand (T-strand) at the origin of transfer (oriT), forming a covalent 
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5’-phosphotyrosine intermediate (16, 19-23). The nicked T-strand moves from 
the donor cell (plasmid+) to the recipient cell (plasmid-) via an intercellular 
junction mediated by a Type IV secretion system (reviewed (19, 24, 25)). The 
relaxase completes DNA transfer by reversing the covalent phosphotyrosine 
linkage and releasing the T-strand. In the F plasmid, this relaxase is located in 
the N-terminal domain of a large multifunctional protein, TraI (DNA Helicase I) 
(22, 23, 26-28). Some conjugative relaxases utilize one active site tyrosine (e.g., 
IncQ RSF1010 MobA (29), IncP RP4 TraI (30, 31), IncI R64 NikA (32), 
Agrobacterium Ti VirD2 (33), Tn5252 MocA/BmgA (34); where “R” indicates 
plasmids that propagate antibiotic resistance). F-like relaxases (e.g., IncF R1 and 
R100 plasmid TraIs (28), IncN R46 and pCU1 TraIs (35), IncW R388 TrwC (36), 
Pseudomonas IncP9 pWW0 TraC (37)) maintain a conserved, bifurcated 
constellation of two to five tyrosines near their N-termini. The most common 
arrangement is four tyrosines (Y1-Y4; tyrosines 16, 17, 23, and 24 in F TraI), with 
pairs Y1/2 and Y3/4 separated by a variable linker region. Crystal structures 
show all four tyrosines are proximal to a bound metal ion (this study and others 
(38-41)). Optimal relaxase cleavage, ligation and transfer of ssDNA require the 
metal ion and two catalytic tyrosines, one from each pair (42).  F TraI relaxase 
shares significant sequence identity with relaxases of many R plasmids (e.g., 
98% with R100 TraI); thus, the F plasmid serves as a model system for 
examining conjugative plasmids and the inhibition of conjugative transfer. 
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In this study, we first sought to understand the role that the relaxase 
enzyme plays in the initiation and termination of DNA conjugation, and then 
sought to use that information to identify potent relaxase-specific inhibitors.  Our 
results establish that the conjugative DNA transfer process can be selectively 
disrupted by relaxase-targeted compounds, including some clinically-approved 
drugs. This is a potentially novel antimicrobial approach, one that could be used 
to purge from microbial populations the bacteria capable of propagating antibiotic 
resistance genes. 
 
2.2 Results 
We determined the 2.4 Å crystal structure of the 300-residue N-terminal 
relaxase domain of F plasmid TraI (N300) with a tyrosine 16 to phenylalanine 
mutation (Y1 of F TraI; Y16F) (Fig. 1a; Table 2). The structure of N300 is similar 
to those of a 330-residue F TraI fragment (39, 41) (N330) and the relaxase 
domain of R388 TrwC (38, 40) (Fig. 5). Crystallization required a 9-base single-
stranded DNA (ssDNA) oligonucleotide consisting of the F oriT nick site 
sequence. In spite of the Y16F mutation, which reduces N300 DNA cleavage 
600-fold, we observed electron density for just one DNA base in the active site 
(Fig. 1a). We interpreted this as the oriT thymidine immediately upstream of the 
scissile phosphate (-1 Thy). We also observed density for a bound metal ion, 
chelated by three conserved histidine sidechains (soft ligands, i.e. uncharged 
and high polarizability). Despite unusual soft chelation, we interpret the bound 
metal as a divalent magnesium ion (a hard center, i.e. low polarizability and a 
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preference for charged ligands) based on bond lengths, electron density, and 
octahedral coordination. A survey of magnesium-binding proteins in the Protein 
Data Bank revealed that the chelation of Mg2+ by neutral residues is diagnostic of 
a site that simultaneously binds to multiple phosphate groups (Table 2). Mutation 
of the metal-chelating residue histidine 159 to glutamic acid (thus reducing the 
effective charge of the metal site) eliminated relaxase activity (Fig. 6).  These 
data indicate that the 2+ charge on the bound metal ion is critical to relaxase 
function.  
 
We then considered models for conjugative DNA transfer that would 
require the observed 2+ metal ion and two catalytically-competent tyrosine 
residues (Fig. 1b).  In the case of Simple Transfer (green), a single catalytic 
tyrosine is sufficient for successful intercellular DNA transfer.  However, if the 
free 3’-hydroxyl product of relaxase-mediated DNA cleavage becomes a 
substrate for Concomitant Plasmid Replication (CPR; purple), analogous to 
rolling circle replication (43), then two tyrosines would be required to resolve the 
replicative oriT intermediate and release the T-strand to complete transfer. CPR 
events explain the reported low frequency generation of greater than unit-length 
conjugative plasmids (44). Although CPR may not be the primary conjugative 
pathway, plasmids with relaxases capable of resolving CPR intermediates would 
be expected to have a selective advantage. Single-tyrosine relaxases could 
achieve resolution of CPR intermediates through relaxase multimerization (45) or 
cooperation with a second non-relaxase protein (46). The ability to resolve 
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undesirable replication products would also confer oriT specific recombinase 
activity between plasmids (47, 48) or between tandem oriT repeats on the same 
plasmid (46, 49). However, for our purposes, a key prediction that arose from this 
model is that multi-tyrosine relaxases are capable of accommodating two 
phosphotyrosine intermediates simultaneously within their active sites. The need 
to handle dual phosphotyrosine intermediates would explain the key features of 
the TraI relaxase outlined above: the presence of two catalytically-competent 
tyrosines and the requirement for a metal ion with an obligate 2+ charge. 
 
We examined the catalytic role of the relaxase active site divalent metal 
ion, which is coordinated by three conserved histidine residues and has been 
interpreted as either magnesium or zinc (40, 41).  While zinc coordination by 
histidines is common, the exclusive chelation of a hard magnesium ion by soft 
imidazole side chains is unusual.  However, magnesium may be essential to 
relaxase function, as the activity of several relaxases are enhanced by Mg2+ (29, 
50). As stated in the main body of this study, a survey of magnesium-binding 
proteins in the Protein Data Bank (51) revealed that the chelation of Mg2+ by 
neutral residues is diagnostic of polyphosphate binding (Table 2).  We tested 
whether the 2+ charge on the metal ion bound to the F TraI relaxase was 
required for enzyme function by mutating one of the three coordinating histidine 
residues (H159) either to a neutral glutamine residue (H159Q) or to an acidic 
glutamic acid residue (H159E). The nearly isostructural H159Q mutation had no 
effect on enzyme function, generating cleavage and crossover activity 
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approximately 95% of wild type TraI. The H159E mutation, however, which would 
reduce the effective charge on the bound metal ion to 1+, essentially eliminated 
enzyme function, generating a 12-fold decrease in cleavage activity, no 
measurable crossover activity, and a three order-of-magnitude decrease in 
conjugative transfer activity. Thus, a 2+ charge on the bound metal ion is 
essential for the catalytic activity of the TraI relaxase, particularly the generation 
of DNA crossovers and successful conjugative DNA transfer. 
 
Based on the prediction that multi-tyrosine relaxases employ two 
simultaneous phosphotyrosine intermediates coordinated to one magnesium ion, 
we hypothesized that simple bisphosphonates would bind the magnesium center 
and thus inhibit F TraI relaxase activity and conjugative transfer. To test this 
hypothesis, a kinetic assay using fluorophore-labeled oriT ssDNA for cleavage by 
the F TraI relaxase domain (TraI N300) was developed to complement existing 
radiolabel-based techniques (52, 53).  Imidodiphosphate (PNP), a simple and 
relatively stable bisphosphonate, was the first compound examined in this assay 
(Fig. 2a).  We found that PNP is a nanomolar inhibitor of TraI relaxase activity in 
vitro. Analysis of cleavage velocity curves revealed that PNP is a mixed-type 
(specifically, noncompetitive) inhibitor of TraI, with apparent competitive (Kic,app) 
and uncompetitive (Kiu,app) inhibition constants of 2.0-2.4 nM and 2.7-3.5 nM, 
respectively. Thus, a simple bisphosphonate serves as a potent inhibitor of a 
multi-tyrosine relaxase activity in vitro.  
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To determine whether PNP derives its inhibitory power by binding to the 
TraI relaxase active site, TraI N300 Y16F crystals were soaked with PNP and the 
x-ray structure determined to 3.0 Å resolution (N300+PNP; Table 1). As in the 
N300 structure, three of the six magnesium octahedral coordination positions are 
filled by histidine side chains, the fourth by the 3’-hydroxyl of the scissile 
thymidine, and the fifth is occluded by the Y16F side chain (Fig. 2b).  Unlike the 
N300 structure, a 5σ simulated-annealing omit electron density peak appears in 
the sixth coordination position (Fig. 8), indicating the binding of a single PNP 
phosphate group within 3.7 Å of the magnesium ion.  The second PNP 
phosphate was not observed, due either to disorder or, more likely, to hydrolysis 
by a water molecule activated by the adjacent 2+ metal (54-57).  The N300+PNP 
structure supports the conclusion that PNP inhibits TraI by binding to the 
relaxase catalytic site. 
 
The N300+PNP structure revealed a novel phosphate binding site, which 
allowed us to model the second phosphotyrosine intermediate in the relaxase 
active site. By rotating  the first alpha helix (αA; lower right corner Fig. 1a) to 
match the orientation observed in the R388 TraI homologue, TrwC (40), and 
extending helicity through tyrosine 24 (Y4 of F TraI), tyrosine 23 (Y3 of F TraI) 
reorients such that its side chain hydroxyl overlaps with the N300+PNP 
phosphate position (Fig. 2c). In this orientation, tyrosine 24 also makes an 
aromatic stacking interaction with the side chain of tryptophan 278 (W278), a 
residue that is conserved in relaxases that have Y3/4 pairs. This model explains 
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how two phosphotyrosines, one at Y16 and one at Y23, can be accommodated 
within the active site, and in the process fulfill the octahedral coordination 
geometry of a bound magnesium ion.  
 
A variety of compounds were then examined for their ability to inhibit the F 
TraI relaxase in vitro.  A coarse screen (200 nM concentrations and pH 7.4) of 
eleven bisphosphonates and three negative controls (sodium chloride, dibasic 
potassium phosphate, and ampicillin, none of which exhibited relaxase inhibition) 
yielded five additional inhibitors: methylenediphosphonic acid (PCP); 
iminobis(methylphosphonic acid) (PCNCP); etidronic acid (ETIDRO); clodronic 
acid (CLODRO); and 1,2-bis(dimethoxyphosphoryl)benzene (PBENP) (Fig. 3). 
Results from this screen reveal that effective inhibitors have two phosphonate 
moieties separated by three or fewer atoms and have no additional negative 
charge at pH 7.4.  Four clinically-approved bisphosphonates were tested; these 
drugs are used to treat bone loss by inhibiting farnesyl diphosphate synthase 
(reviewed (58)). The simplest, ETIDRO and CLODRO, inhibited the TraI 
relaxase, while pamidronic acid and neridronic acid (PAMDRO, NERDRO, 
respectively), which have an alkyl-amine side chain, did not.  Two other inhibitors 
identified, PCP and PNP, have been used as radioisotope carriers in humans 
(59, 60). Pyrophosphate was not examined due to its rapid hydrolysis in aqueous 
solution.  The simplest inhibitors, PCP, ETIDRO and CLODRO, were then 
characterized further using a kinetic assay and exhibited purely competitive 
inhibition, with Kic,app values ranging from 3-145 nM (Fig. 9).  Taken together with 
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the PNP results, these data validate the prediction that F-like conjugative 
relaxases can accommodate two phosphotyrosine intermediates simultaneously 
within their active sites. Significantly, these data also establish that 
bisphosphonates (including clinically-approved compounds) potently inhibit the in 
vitro relaxase activity of F TraI with Ki values in the nanomolar range. 
 
We next asked whether PNP could impact conjugative DNA transfer 
between living bacterial cells.  F+ E. coli  were mated with F- E. coli  in dilute 
media and in the presence of increasing concentrations of PNP. The resulting 
mixture was applied to agar plates with antibiotic selection for transconjugants 
(newly formed F+ cells). Colony counts revealed that PNP inhibited DNA transfer 
with a half-effective concentration (EC50) of approximately 10 µM, the lowest 
concentration tested in this assay (Fig. 4a).  We also found that PNP selectively 
kills F+ donor cells with an EC50 of <10 µM (compared to low millimolar EC50 
against F- recipient cells).  This suggests that the TraI relaxase sensitizes F+ cells 
to a toxic effect of PNP. Minimal cell growth was observed in control mating 
mixtures, so decreases in donor cell count relative to controls are attributed 
primarily to cell death rather than to a lack of cell growth. Thus, inhibitor-
dependant decreases represent bacteriacidal rather than bacteriastatic effects. 
Strains containing an F plasmid lacking the TraI gene (F+/TraI-) or containing an 
F plasmid with the four active site tyrosines mutated to phenylalanine (F+/TraI 
4Y-F) behaved like F- cells in this assay, in that they were resistant to the lethal 
effects of PNP.  The impact on DNA donor cell survival depends on the presence 
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of a catalytically active TraI relaxase.  Thus, the simple bisphosphonate PNP 
enters living bacteria, inhibits conjugative DNA transfer, and selectively kills cells 
in an active relaxase-dependent manner. 
 
A fluorescence-based 96-well assay was then employed to examine 
further these effects and to screen additional compounds for the ability to impact 
cell survival and DNA transfer in living bacterial cells. This higher-throughput cell 
enumeration assay utilized an oxygen-quenched fluorophore imbedded within a 
hydrophobic gel; the concentration of live (oxygen consuming) cells is 
proportional to fluorescence  (61).  The six compounds effective at inhibiting TraI 
relaxase activity in vitro (PNP, PCP, PCNCP, PBENP, CLODRO, ETIDRO; Fig. 
3), along with two controls (PAMDRO and K2HPO4 [PO4]) were examined for 
their impacts on F+ and F- cell survival and on DNA transfer (Fig. 4b, 4c).  
PAMDRO and PO4, which had no effect on TraI relaxase activity in vitro, showed 
little effect on cell survival and DNA transfer in these cell-based assays, 
exhibiting EC50 values greater than the highest concentrations tested (10 mM 
and 100 mM, respectively) and no selectivity for F+ over F- cells.  In contrast, all 
six potent in vitro TraI relaxase inhibitors were also effective in living E. coli cells.  
EC50 values for inhibiting F+ donor cell survival ranged from 10 µM (ETIDRO) to 
16 nM (PCNCP), and for inhibiting conjugative DNA transfer from 31 µM (PNP) to 
110 nM (CLODRO).  These compounds have little effect on F- recipient cells, 
with EC50 values ranging from 0.34 mM (ETIDRO) to >100 mM (PBENP), which 
represents 30- to 106-fold selectivity for F+ cells, respectively.  In general, PNP 
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and PBENP were more effective at inhibiting F+ cell survival, ETIDRO and 
CLODRO were more effective at inhibiting DNA transfer, and PCP and PCNCP 
were effective against both F+ cell survival and DNA transfer (Fig. 4b, 4c; Fig. 3). 
The ranges for EC50 values (Fig. 4b) were derived considering the error bars 
present in the survival curves (Fig. 4c).  Thus, for the most extreme case of 
ETIDRO, the median EC50 for transfer inhibition is 330 nM with a range of 1.1 µM 
to <10 pM (Fig. 10). Taken together, however, these data establish that 
relaxases can be inhibited with nanomolar affinity within living bacterial cells and 
that this inhibition both limits DNA transfer and selectively kills microbes 
harboring conjugative plasmids. 
2.3 Discussion 
This study outlines a potentially novel antimicrobial paradigm that 
specifically targets the DNA relaxase enzyme required to initiate and terminate 
the process of bacterial conjugation. The compounds identified could be used 
along or in combination with existing antibiotics to treat recalcitrant bacterial 
infections.  Other antibiotics and natural extracts have been reported to disrupt 
conjugative DNA transfer and the presence of plasmids within actively dividing 
bacterial cells(5-15).  In each case, however, the macromolecular target of those 
compounds was not understood and their mechanism of action has not been 
determined.  We took a “bottom up” approach targeted DNA conjugation by 
considering first the mechanism and role of a single enzyme (the DNA relaxase) 
in this process, and then identifying inhibitors to test a specific mechanistic 
hypothesis (that two phosphotyrosine intermediates can be accommodated in the 
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relaxase active site).  While our data was collected on the relaxase from the well-
established F plasmid that was first identified in 1946(2), the F conjugative 
machinery shares up to 99% sequence identify with R plasmids that transfer 
antibiotic resistance in the wild.  Thus, our approach is likely to be effective 
against a range of plasmids involved in propagating a range of resistance genes 
and virulence factors, many of which play an important role in clinical infections 
(62-64). 
 
In addition to inhibiting DNA transfer, we show that simple 
bisphosphonates selectively purge populations of bacteria containing a 
conjugative plasmid with an active relaxase enzyme.  However, because TraI is 
F plasmid encoded, not an essential E. coli enzyme, and was not expected to 
play a significant role in isolated F+ cells, this relaxase-dependent cell lethality 
was a surprise. Several mechanisms could be envisioned to explain this 
observation, and future studies will be required to distinguish between them. One 
possibility is that relaxases engage in cycles of plasmid DNA cleavage and 
religation that are uncoupled from mating and conjugative DNA transfer, and that 
the disruption of that process results in a competitive disadvantage relative to 
cells without conjugative plasmids. Indeed, inspection of Fig. 4C reveals that a 
direct competition appears to exist between plasmid propagation and donor cell 
survival (note particularly PNP, PCNCP, PBENP, CLODRO).  F+ donor cell 
survival is enhanced at higher bisphosphonate concentrations to the detriment of 
plasmid propagation via conjugative transfer. These observations suggest a 
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classic “zero-sum game” in which toxic relaxase-specific bisphosphonate 
inhibitors pit the interests of endosymbiont plasmids against those of their 
bacterial hosts. 
 
We show that the clinically-approved bisphosphonates etidronate 
(Didronel®) and clodronate (Bonefos®), but not other bisphosphonate 
therapeutics, are potently effective at killing F+ cells and preventing conjugative 
DNA transfer.  These particular compounds could also be combined with existing 
antibiotics to create potent antimicrobial cocktails. Etidronate and clodronate 
exhibit low absorption (65, 66) and can be administered at high oral doses (Table 
3).  Extrapolating from our results, approved doses of etidronate and clodronate 
would be expected kill >90% of plasmid+ cells and to stop >80% of conjugative 
transfer within the gastrointestinal track. Such results are relatively mild, given 
the large bacterial populations present in the gastrointestinal tract or at wound 
sites, but may be enough shift the balance toward success in a variety of 
recalcitrant clinical infections, especially given the prevalence of conjugative 
plasmids within multi-drug resistant bacterial strains.  The treatment of skin 
infections, primary sites of nosocomial antibiotic resistance transfer, using the 
topical applications of bisphosphonates may also be effective.  In summary, this 
study establishes conjugative relaxases as a unique antimicrobial target.  Our 
results suggest that approved therapeutics could have an immediate impact, 
alone or in combination with existing antibiotics, in the prevention of resistance 
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propagation during clinical treatment of bacterial infections, and in extending the 
lifetime of our antibiotic arsenal. 
2.4 Materials and Methods 
2.4.1 Protein Expression and Purification 
An amino-terminal 300 residue F plasmid TraI construct, bearing a 
tyrosine to phenylalanine mutation at position 16 (N300 Y16F), was cloned into 
IMPACT® vector pTYB2 (New England Biolabs) for expression as a C-terminal 
intein-chitin-binding-domain (CBD) fusion. Protein was expressed in either E. coli 
BL21 (DE3)/pLysS or HMS174 (DE3)/pLysS and was purified as per the 
standard IMPACT® protocol.   Briefly, cellular extracts were prepared and 
incubated with 1 mL of Chitin Resin (New England Biolabs) per liter of cell 
culture. The resin was washed and incubated with 50 mM dithiothreitol (DTT) 
overnight to cleave the relaxase from its CBD tag. The DTT laden eluent was 
extensively dialyzed in 20 mM NaCl and 20 mM Tris-HCl (pH 7.5).  The resulting 
N300 Y16F was >95% pure by SDS-PAGE, and was concentrated to 3 mg/mL 
for crystallization in 50 mM NaCl, 10% glycerol, and 10 mM Tris-HCl (pH 7.5) 
prior to flash-freezing in liquid nitrogen for storage at -80 °C. Protein for functional 
and kinetic assays was concentrated to 42.3 µM in 150 mM NaCl, 50% glycerol, 
and 10 mM Tris-HCl (pH 7.5) for long-term storage at -80 °C. 
2.4.2 Oligonucleotides 
A 9-base single-stranded DNA oligonucleotide (9mer) derived from the F 
plasmid oriT (5’-GGT GT^G GTG-3’, where ^ is the scissile phosphate) was 
synthesized for crystallization at the UNC Lineberger Comprehensive Cancer 
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Center Nucleic Acids Core Facility. Labeled oligonucleotides for fluorescence 
fluorescent kinetic assays were synthesized by Integrated DNA Technologies 
(IDT). For the initial kinetic assay the substrate oligonucleotide was a 5’-biotin 
(bio) labeled 29mer (“b29”; 5’-bio-TTT GCG TGG GGT GT^G GTG CTT TTG 
GGT GG-3’). The complementary fluorescent probe oligonucleotide was a 5’-6-
carboxyfluorescein (56FAM™) labeled 15mer (“downF”; 5’-56FAM-CC ACC CAA 
AAG CAC C-3’). The b29 substrate molecule was derived from the F plasmid 
oriT. The downF probe is complementary to the downstream portion of b29. The 
melting temperature was 50.8° C for downF versus b29 (15 base-pairs) , as 
calculated with IDT OligoAnalyzer™ 3.0 with default parameters. For later kinetic 
assays, the substrate oligonucleotide was a 5’-biotin (bio) labeled and 3’-56FAM 
labeled 27mer (“Bio19'8FAM”; 5’-bio-CT TGT TTT TCG TGG GGT GT^G GTG 
CTT T -3’). The Bio19'8FAM substrate molecule has a larger portion of the F 
plasmid oriT than does the b29 oligonucleotide. Oligonucleotides for site directed 
mutagenesis were synthesized by Integrated DNA Technologies.  
 
2.4.3 Crystallization and Structure Determination 
N300 Y16F crystals grew in a DNA-dependent manner in 75 mM sodium 
nitrate, 14% w/v PEG 3350, 10 mM spermine, and 110 µM 9mer. These rods 
were cryoprotected via a two-second dip in 150 mM sodium nitrate, 35% w/v 
PEG 3350, and 10 mM spermine and flash cooled in liquid nitrogen for storage 
and transport. Crystals employed for the PNP-bound structure were soaked for 
24 hours in 200 mM ammonium nitrate, 40% w/v PEG 3350, and 1 mM N,N-
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imidobisphosphonate (PNP) and flash cooled. Rods 200 × 30 × 20 µm in size 
were generated by hanging drop vapor diffusion (>35 days of growth) and 
diffracted to between 2.9 Å and 3.4 Å in-house. Data sets were collected at the 
Advanced Photon Source (APS) at Argonne National Laboratoy (ANL), at 
Southeast Regional Collaborative Access Team (SER-CAT) Sector 22 Insertion 
Device Beamline (22-ID) and the General Medicine and Cancer Institutes 
Collaborative Access Team (GM/CA-CAT) Sector 23 Insertion Device Beamline 
(23-IDin; for the PNP complex). Crystals were of space group of P212121 and 
contained two protein monomers in the asymmetric unit (Table 1).  X-ray 
diffraction data were indexed and scaled with the HKL2000 or MOSFLM (CCP4) 
(67).  Initial phases were determined by molecular replacement in Molrep (CCP4) 
(67) with the apo-TraI structure (Protein Data Bank accession 1P4D (41)) as a 
search model. Model adjustment was completed with O (68) and σa-weighted 
electron density maps (69), and structures were refined using torsion angle 
dynamics and the maximum likelihood target as implemented in CNS (70). 
Structure figures were constructed in PyMol v0.98 (71).  
 
2.4.4 Functional Assays 
Both wild-type and mutant TraI proteins (either full length protein or TraI-
N300) were examined in oligonucleotide cleavage (DNA nicking), strand transfer 
(DNA religation) and liquid mating (DNA transfer) assays. The oligonucleotide 
cleavage reaction mixture (10 µl) contained 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 6 mM MgCl2, 20% glycerol, 1 pmol 5'-end labeled 22-mer, and 1 pmol TraI 
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(unless otherwise stated).  Reactions were assembled at room temperature and 
incubated at 37°C for 20 minutes.  Reactions were stopped by the addition of 
SDS to 0.2%, and incubation was continued at 37°C for 10 minutes.  Ten µl 85% 
formamide, 50 mM EDTA, 0.1% dyes were added to the reaction, the products 
were denatured at 100°C for 3 minutes and analyzed on a 16% polyacrylamide, 8 
M urea denaturing gel.  The gels were electrophoresed at 25 watts in 1xTBE (90 
mM Tris-borate and 2 mM EDTA) and visualized using a PhosphorImager 
(Molecular Dynamics).  Markers were prepared as described previously (72).  
Strand transfer reactions were performed in a manner similar to the 
oligonucleotide cleavage assay except after the 20-minute incubation, 1 pmol of 
a second unlabeled oligonucleotide of differing length containing the F plasmid 
nic site was added to the reaction and incubation was continued at 37°C for 1 
hour.  The reaction was stopped and analyzed using the procedure described 
above.  Liquid mating assays were performed as previously described (26) 
except HMS174 cells were utilized instead of HMS174 (DE3) to reduce the 
constitutive expression of the complementing protein.  Briefly, cells containing 
pOX38T∆TraI and the appropriate complementing plasmid were grown overnight 
in the presence of appropriate antibiotics.  Overnight cultures were used to 
inoculate cultures that were grown at 37oC to mid-log phase (2-3 hours) in the 
absence of antibiotics.  Donor cells were mixed (1:10) with recipient cells, 
incubated at 37oC and then plated to select for transconjugants and 
counterselect for donors and recipients.  Site-directed mutations in the traI gene 
were created using mutagenic primers and the site-directed mutagenesis 
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protocol supplied by Stratagene.  pTYB2-traIN300 served as the template for 
PCR. The resulting clones were sequenced to confirm the presence of the 
engineered mutations and the absence of unintended mutations.  A unique 700 
bp NdeI-StuI fragment of traI containing the engineered mutations was removed 
from pTYB2-traIN300 and ligated into the full length traI gene in pET11c-traI that 
had been digested at unique NdeI and StuI sites to create the mutant pET11c-
traI derivatives that were at utilized in genetic complementation assays.  
 
2.4.5 Kinetic Assays 
2.4.5.1 Kinetic Assay Formulations 
Reaction Buffer: 6.42 mM MgCl2, 20.5% glycerol, 153.9 mM NaCl, and 
51.3 mM Tris-HCl pH 7.5. Streptavidin Wash Buffer (Tris buffered saline, 
TBS/Tween): and 150 mM NaCl, 25 mM Tris-HCl pH 7.5, and 0.05% Tween-20. 
Stopping Buffer: 1.2% sodium-dodecyl sulfate (SDS), and 300 mM EDTA pH 10. 
TE Buffer: 1 mM EDTA, and 10 mM Tris-HCl pH 7.4. Fluorescence Buffer: 80% 
glycerol, 200 mM Tris-HCl pH 8.0. Short-term N300 stock (for storage at -20 °C): 
50% Reaction Buffer, 49.8% glycerol, 0.2% long-term protein solution (84.6 nM 
final N300 concentration). All 5x stocks except Probe stocks were diluted in 
Reaction Buffer. 5x Enzyme Stock: 8.4 mL short-term N300 stock diluted to 2.02 
nM N300. 5x Inhibitor Stocks: imidodiphosphate (PNP) at 0-50 nM in Reaction 
Buffer. 5x Substrate Stock: b29 oligonucleotide was diluted to 19.6-158.5 mM 
each, by 3-fold serial dilutions. 5x Probe Stocks: 23.5-190.2 mM (1.2-fold molar 
excess) downF oligonucleotide in TE Buffer. All reactions and procedures 
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involving downF were assembled and performed in low-light conditions. Solutions 
and microtiter plates containing downF were kept in foil-lined containers at all 
times to prevent photobleaching. In Later kinetic assays, different substrate 
dilution schemes were used, Fluorescence Buffer was abandoned in favor of 
Streptavidin Wash Buffer, and the Stopping Buffer SDS concentration was 
reduced to 0.2%. 
 
2.4.5.2 Fluorescent Kinetic Assays 
Two oriT derived oligonucleotides, b29 and Bio19'8FAM, were designed 
for binding and cleavage by TraI based on past studies (73) in two phases. The 
Initial phase includes the initial uninhibited characterization of N300 
oligonucleotide cleavage, all inhibition studies with PNP, and a blind rough 
screen of all listed inhibitor candidates (Fig. 3). The Later phase used improved 
oligonucleotide design and included the inhibitor characterizations of PCP, 
ETIDRO, and CLODRO. The overall method is similar to those described 
previously for the study of TraI and R388 TrwC (27). Reactions were assembled 
from 16 µL of 5x Substrate Stock, 16 µL of 5x Inhibitor Stock, and 32 µL of 
Reaction Buffer. 80 µL reactions were initiated with 16 µL of 5x Enzyme Stock 
and raised to 37 °C. 10 µL samples were removed at eight time points and 
stopped. In Initial assays, reactions were stopped with 10 µL of Stopping Buffer 
at room temperature and placed on a 100 °C heat block for one minute, spiked 
with 2 µL of 5x Probe Stock while still hot, and incubated at 37 °C for 10 minutes 
(see Kinetic Assay Formulations for probe handling). In Later assays, reactions 
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were stopped with 2 µL of Stopping Buffer at 80 °C. Samples were diluted to 65 
µL with Streptavidin Wash Buffer and transferred to streptavidin-coated microtiter 
plates (Thermo Electron Biobind™ Assembly white 96-well plates  for Initial 
assays; Reacti-Bind™ High Binding Capacity black 384-well plates for Later 
assays). Plates were incubated at 37 °C for 45 minutes (Initial assays) or one 
hour (Later assays). Plates were washed with at least 5-fold excess Streptavidin 
Wash Buffer (in an inverted position to prevent excess biotinylated species from 
transferring between wells; in Later assays this step occurred after reading the 
plate to determine total oligonucleotide content). Washed wells were then filled 
with either 65 µL of Fluorescence Buffer (for optimum 6-FAM™ fluorescence; 
Initial assays) or with one well volume of Streptavidin Wash Buffer (Later 
assays). Plates were read in a BMG Labtech FLUOstar Optima (Initial assays) or 
Pherastar (Later assays ) with a 490 nm excitation and 520 nm emission filters 
(10 nm bandpass) with the gain optimized for maximum signal.  
 
2.4.5.3 Kinetic Data Processing 
All timecourses were fitted by nonlinear regression with un-weighted least-
squares methods using SigmaPlot 8.0 (also used for graph construction). 
Timecourses were manually culled for very high signal (incomplete washing) or 
very low signal (physical damage to streptavidin coating). Timecourses were 
scaled to reflect fractional cleavage and replicate timepoints were averaged (n = 
1-8; mean n = 3.52). The averaged curves were fitted to a simple, three-
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parameter exponential decay equation (Equation 1), and converted into units of 
concentration.  
Equation 1: 
btaeysignal −+= 0  
where t is time in seconds, y0+a is the initial signal, b is a constant that 
determines the shape of the curve. Integration of the overall rate equation for 
fitting of timecourses was prohibitive. The derivative of the decay equation at 
zero time was taken as the negative of the initial reaction velocity (v0; equals ab 
from Equation 1). Michaelis/Menton curves (v0 versus substrate concentration) 
were constructed for each inhibitor concentration. 
 
2.4.5.4 Calculation of Kinetic Constants 
Competitive (Kic) and uncompetitive (Kiu) inhibition constants were 
estimated from Vmaxapp and Kmapp values obtained with one of two methods: first, 
velocity curves were fitted to the simple modern Michaelis/Menton equation 
(Equation 2) by nonlinear regression with un-weighted least-squares method in 
SigmaPlot 8.0; second, the Cornish-Bowden/Eisenthal scale-free direct linear 
plot method was applied as implemented in the Exploratory Enzyme Kinetics 
Macro for SigmaPlot 8.0 (74-78). These methods produced virtually identical 
results, so in Later assays, only the former method was used. 
Equation 2: 
SK
SV
v app
m
app
+=
max
0  
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where Kmapp is the apparent Michaelis constant and Vmaxapp is the maximum 
reaction velocity. For PNP, competitive (Kic) and uncompetitive (Kiu) inhibition 
constants were estimated from extrapolation of the negative of ordinate 
intercepts of Kmapp/Vmaxapp-versus inhibitor concentration and 1/Vmaxapp-versus-
inhibitor concentration, respectively. Definitions for Vmaxapp and Kmapp (Equations 
4-5) were obtained by comparing the equation for mixed inhibition (Equation 3) 
with the Michaelis/Menton equation (Equation 1) and setting Kic and Kiu 
individually to infinity. 
Equation 3: 
)/1()/1(
max
iuicm KISKIK
SV
v +++=  
where v is reaction velocity, S is substrate concentration, and I is inhibitor 
concentration. 
Equation 4, 5: 
iu
app
KI
V
V
/1
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mapp
m KI
KV
K
/1
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+=  
where Vmax is the uninhibited maximum velocity and Km is the uninhibited 
Michaelis constant. For inhibitors other than PNP, no uncompetitive inhibition 
was observed. Kic for these inhibitors was estimated by fitting inhibited velocity 
curves to Equation 3 with Vmax and Km set as determined in uninhibited assays 
and Kiu set to zero. 
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2.4.6 Mating and Cell Toxicity Assays 
2.4.6.1 Mating, selection on solid substrate 
Mating assays were performed as described (26). All cell strains are E. 
coli variants. Briefly, the donor strain (JS10) contains pOX38T, a tetracycline 
resistant and conjugation capable mini-F-plasmid, while the recipient strain (JS4) 
is F- and streptomycin resistant.  Donor and recipient strains from saturated, 
antibiotic selected overnight cultures were diluted 1:50 and then grown at 37 ºC 
in the absence of selection to an OD600 of approximately 0.6.  Donors and 
recipients were then mixed at a ratio of 1:9 in the presence of the desired 
concentrations of PNP (e.g., 10, 100 µM, 1, 10 mM) and incubated at 37ºC for 
five minutes.  Mating mixtures were diluted tenfold into broth containing the 
desired PNP concentration and incubated for an additional 30 minutes.  
Following mating, the mixtures were vortexed to disrupt mating pairs and serially 
diluted into 0.9% sterile saline. Dilutions predicted to result in 300-500 colonies 
on positive control plates were plated on agar plates containing both 
streptomycin and tetracycline in order to select for transconjugants. Eight 
replicate samples of each final dilution were plated and the colony counts culled 
for outliers at 95% confidence and then averaged.  
 
2.4.6.2 Cell Toxicity, selection on solid substrate 
These assays proceed as per the Mating Assays above, save that strains 
are not mixed and thus no mating occurs. In addition to JS4 and JS10 strains, 
these assays used a strain with a pOX38T containing an inactive TraI gene 
42 
(JS11) and a derivative of this strain that was co-transformed with a 
complementing pET11d plasmid containing a TraI mutant (JS11quad; all four 
TraI active tyrosines mutated to phenylalanine). JS11 cells have tetracycline 
resistance. JS11quad cells are tetracycline and ampicillin resistant. 
 
2.4.6.3 Fluorescent Mating & Toxicity, selection in liquid media 
Growth, mating and preparation were performed as described above. 
Mating was performed in the presence of various inhibitors from low picomolar to 
high millimolar concentrations. Substances shown to be poor in vitro inhibitors of 
F TraI N300 (potassium phosphate and pamidronate) were used as negative 
controls. Selections for donors, recipients and transconjugants were performed in 
Oxygen Biosensor™ 96-well round bottom plates (BD Biosciences). Cell 
concentrations were quantified by fluorescent doubling time analysis as 
previously described (61). Fluorescence was quantified on a Pherastar 
fluorescent plate reader (BMG). 
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2.5 Figure Legends 
Figure 1.  F TraI N300 Y16F, Bound to the Scissile Thymidine, and a Two-
Path Model of F-like Bacterial Conjugation.  
A. N300 Y16F active site without PNP (2.4 Å resolution, orange sticks and 
ribbons). A metal ion (blue sphere) is chelated by three histidines and the -1 
Thy nucleotide 3’-hydroxyl. Phenylalanine 16 (Y16F) occludes a fifth 
octahedral coordination site. Y16F is at the C-terminal of the first alpha helix 
(αA). 
B. Conjugation is initiated by oriT on the T-strand (red strand) cleavage by the 
first tyrosine, forming a covalent phosphotyrosine intermediate (red circle). 
Transfer with Concomitant Plasmid Replication diverges from Simple Transfer 
when the free 3’-hydroxyl, left by the initial cleavage, becomes a substrate for 
replication (blue strand). Replication creates a new oriT, necessitating 
resolution by a second cleavage event and phosphotyrosine formation (purple 
circle) before ligation of the original T-strand. This results in a dual-
phosphotyrosine intermediate. 
 
Figure 2. Relaxase Inhibition by PNP. 
A. N300 oriT ssDNA cleavage velocity (v0) inhibited by 0, 1, and 10 nM 
imidodiphosphate (PNP; red, orange, and yellow, respectively; error bars 
represent compounded standard errors from timecourse parameter 
estimates; n>3). Competitive/uncompetitive inhibition constants (Kic/Kiu) and 
uninhibited Michaelis constant/maximum velocity (Km/Vmax) are from 
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nonlinear regression and Cornish-Bowden/Eisenthal direct linear plot 
analyses. Velocities for 100 and 10,000 nM PNP (dark and light blue 
crosses, respectively), estimated from low signal, were excluded from 
calculations. 
B. N300 Y16F active sites with PNP (3.0 Å resolution; red) and without 
(orange). A metal ion (blue sphere) is chelated by three histidines, the -1 
Thy 3’-hydroxyl, and one PNP moiety (purple). Y16F occludes the sixth 
coordination site. Residues 236-263 and 266 were disordered (small orange 
spheres). 
C. Dual phosphotyrosine intermediate conformation model (red) constructed 
from the N300+PNP structure. Helix αA was rotated ~120° about the helical 
axis to match that of TrwC structure 1OMH, helicity extended through αA’, 
and kinked about histidine 146. Important side chains (red sticks), PNP 
(purple sticks), a hypothetical second phosphate (purple circle), the bound 
metal (blue sphere), and the scissile thymidine (from 1OMH; blue) are 
shown over the TraI active site cleft molecular surface. 
 
Figure 3.  Bisphosphonates Examined for Relaxase Inhibition.  Chemicals 
examined for inhibition of TraI activity and F conjugation and for toxicity versus E. 
coli strains. Boxed chemicals were potent in vitro TraI inhibitors. In cell testing 
showed that PNP / PBENP were most effective at decreasing F+ population, 
CLODRO / ETIDRO at decreasing transconjugant population, and PCP / PCNCP 
were effective at both.  
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Figure 4.  Effects of F TraI inhibitors on E. coli survival and conjugation. F- 
(orange lines/bars/symbols), F+ (red), TraI- (blue), TraI 4Y-F cells (green), and 
transconjugant (DNA transfer; yellow). 
A. Colony counts after imidodiphosphate incubation (normalized versus 
uninhibited controls; averaged). Error bars represent standard deviations of 
the mean (SDOM; n≥5). 
B. EC50s from relative cell counts. Colored bars indicate averaged curve EC50s. 
Error bars represent ±1 SD envelope EC50s (Figure S6). Potent in vitro 
inhibitors are located above a strong black line, negative controls below. 
Selectivities are EC50 ratios for given inhibitors and strains.  
C. Relative cell counts with median EC50s (drop arrows; colored by strain). Error 
bars represent SDOM (n≥3). 
 
Figure 5.  Superimposed TraI and TrwC active sites.  
A. A superimposition of the N300 Y16F structure and TrwC structure 1OMH (4) 
(blue backbone cartoon and sidechain sticks) highlights a conformational shift 
about alpha helix A. This shift rearranges the catalytic tyrosines. The 3’-
hydroxyl position of the scissile thymidine (Thy25 in 1OMH) from all DNA-
bound TraI and TrwC structures (not all shown) varies by less than 0.5 Å, 
though the base moiety position varies greatly (face-to-face ring stacked with 
Y16F in N300 Y16F).  
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B. A superimposition with TraI N330 2A0I (5) (yellow) highlights a loss of order 
C-terminal to alpha helix A, including active site tyrosines 23/24, upon 
extended ssDNA binding. 
 
Figure 6.  TraI 300 wild type vs. TraI 300 H159E Cleavage Activity. 
Cleavage activity, percentage of oriT oligonucleotide cleaved by TraI constructs, 
as measured from radiological intensities of cleaved and uncleaved ssDNA 
bands on an SDS gel. 
 
Figure 7.  Stereo ribbon cartoon of the N300 active with -1 Thy density.  
The N300 Y16F active site of the 2.4 Å structure shows a metal ion (large blue 
sphere) chelated by a histidine triad and the 3’-hydroxyl of the thymidine base 5’ 
to the scissile phosphate (-1 Thy). The sidechain of phenylalanine 16 (Y16F; 
replaces wild type tyrosine 16) occludes a fifth octahedral metal coordination site. 
Backbone atoms are shown as a ribbon cartoon (orange) and important side 
chains and -1 Thy are shown as sticks (orange). The -1 Thy is surrounded by 3 Å 
SA-omit density (green cage). Residues between 235 and 264 and between 265 
and 267 were disordered (small orange spheres). 
 
Figure 8.  The N300 Y16F active site of the 3.0 Å structure with PNP.  
One imidodiphosphate (PNP) moiety chelates a metal ion (large blue sphere) 
along with the histidine triad, and the 3’-hydroxyl of the scissile thymidine base (-
1 Thy). The Y16F sidechain occludes the sixth octahedral coordination site. 
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Backbone atoms are shown as a ribbon cartoon (red) and important side chains 
and -1 Thy are shown as sticks (red). The PNP moiety is shown as sticks 
(purple) surrounded by 3 Å SA-omit density (blue cage). Residues 236-266 were 
disordered (small red sphere). 
 
Figure 9.  N300 inhibition. 
N300 oriT ssDNA cleavage velocity (v0) inhibited by PCP, CLODRO, and 
ETIDRO at zero, low, and high concentrations (red, orange, and yellow, 
respectively; concentrations indicated on the plots; error bars represent the 
standard errors of velocity estimation from timecourse fits; n ≥ 3). The 
competitive inhibition (Kic) and maximum velocity/uninhibited Michaelis constants 
(Vmax/Km are from nonlinear regression. 
 
Figure 10.  EC50 ranges. 
Visual example of EC50 ranges calculations in Figure 4B. EC50s are indicated for 
F+ (red drop arrows) and transconjugants (yellow drop arrows) for the averaged 
the relative cell count curves and for ±1σ error envelope boundaries (shaded 
regions). 
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Figure 2-1 F TraI and Two-Path Model of Conjugation 
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Figure 2-2 Relaxase Inhibition by PNP 
50 
 
 
Figure 2-3 Bisphosphonates Examined for Relaxase Inhibition 
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Figure 2-4 Effects of F TraI inhibitors 
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Figure 2-5 Superimposed TraI and TrwC active sites 
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Figure 2-6 TraI 300 wild type vs. TraI 300 H159E 
Cleavage Activity 
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Figure 2-7 Stereo ribbon cartoon of the N300 active
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Figure 2-8 The N300 Y16F active site of the 3.0 Å structure with PNP 
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Figure 2-9 N300 inhibition 
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Figure 2-10 EC50 ranges 
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Table 2-1 Structure Statistics 
Data collection and refinement N300 - PNP N300 + PNP 
Data collection   
Space group P 212121 P 212121 
Cell dimensions    
    a, b, c (Å) 44.9, 88.3, 127.3 44.5, 86.3, 127.9 
    α, β, γ (°)  90, 90, 90 90, 90, 90 
Resolution (Å) 2.42-500 (2.42-
2.46)
3.00-500 (3.00-
3.11)
Rsym 9.8 (38.2) 13.5 (38.2) 
I/σ 9.6 8.6 
Completeness (%) 97.9 (99.3) 92.8 (72.7) 
Redundancy 5.1 (5.2) 4.1 (3.9) 
   
Refinement   
Resolution (Å) 2.42 3.00 
No. reflections 19,657 10,447 
Rwork / Rfree 21.3 / 27.0 21.4 / 31.2 
No. atoms   
    Protein 4142 4132 
    Ligand/ion 22 26 
    Water 157 45 
B-factors   
    Protein 42.4 37.2 
    Ligand/ion 97.7 93.5 
    Water 40.1 29.0 
R.m.s deviations   
    Bond lengths (Å) 0.0066 0.0085 
    Bond angles (°) 1.22 1.22 
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Table 2-2 Comparison of Magnesium-Binding Sites 
 
* Protein Data Bank crystal structures, ≤2.5 Å resolution, as of Sept. 2003. 
Culled from(1); available at http://tanna.bch.ed.ac.uk/ 
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Table 2-3 Projected Bisphosphonate Doses 
Projected dose 
effectiveness maximum   estimated gut  
decrease in dilute 
media d 
 dose (g/day) 
a 
availability 
b 
concentration (mM) 
c 
F+ transfer F- 
disodium clodronate 
tetrahydrate 
3.2 98% 5.8 93% 91% 55% 
disodium etidronate 1.8 97% 4.7 95% 81% 59%  
a. for a 90 kg patient, from Schering’s Bonefos® and Proctor & Gamble’s 
Didronel® product documentation.   
b. 100% minus serum availability(2, 3). 
c. given estimated availability and 1.5 L average gut volume. 
d.  100 minute exposure, from relative cell count curves, see Fig. 4b-4c. 
 
 
61 
2.6 References 
1. Burrus, V. & Waldor, M. K. (2004) Res Microbiol 155, 376-386. 
2. Lederberg, J. & Tatum, E. L. (1946) Nature (London) 158. 
3. de la Cruz, F. & Davies, J. (2000) Trends Microbiol 8, 128-133. 
4. Mazel, D. & Davies, J. (1999) Cell Mol Life Sci 56, 742-754. 
5. Nakamura, S., Inoue, S., Shimizu, M., Iyobe, S., & Mitsuhashi, S. (1976) 
Antimicrob Agents Chemother 10, 779-785. 
6. George, B. A. & Fagerberg, D. J. (1984) Am J Vet Res 45, 2336-2341. 
7. Oliva, B., Selan, L., Ravagnan, G., & Renzini, G. (1985) Chemioterapia 4, 
199-201. 
8. Michel-Briand, Y. & Laporte, J. M. (1985) J Gen Microbiol 131, 2281-2284. 
9. Palomares, J. C., Prados, R., & Perea, E. J. (1987) Chemioterapia 6, 256-
260. 
10. Molnar, J., Csiszar, K., Nishioka, I., & Shoyama, Y. (1986) Acta Microbiol 
Hung 33, 221-231. 
11. Leite, A. A., Nardi, R. M., Nicoli, J. R., Chartone-Souza, E., & Nascimento, 
A. M. (2005) J Gen Appl Microbiol 51, 21-26. 
12. Weisser, J. & Wiedemann, B. (1987) Antimicrob Agents Chemother 31, 
531-534. 
13. Debbia, E. A., Massaro, S., Campora, U., & Schito, G. C. (1994) New 
Microbiol 17, 65-68. 
14. Spengler, G., Molnar, A., Schelz, Z., Amaral, L., Sharples, D., & Molnar, J. 
(2006) Curr Drug Targets 7, 823-841. 
15. Jung, Y. D. & Ellis, L. M. (2001) Int J Exp Pathol 82, 309-316. 
16. Byrd, D. R. & Matson, S. W. (1997) Mol Microbiol 25, 1011-1022. 
17. Pansegrau, W. & Lanka, E. (1996) Prog Nucleic Acid Res Mol Biol 54, 
197-251. 
18. Lanka, E. & Wilkins, B. M. (1995) Annu Rev Biochem 64, 141-169. 
19. Llosa, M., Gomis-Ruth, F. X., Coll, M., & de la Cruz Fd, F. (2002) Mol 
Microbiol 45, 1-8. 
62 
20. Reygers, U., Wessel, R., Muller, H., & Hoffmann-Berling, H. (1991) Embo 
J 10, 2689-2694. 
21. Matson, S. W. & Morton, B. S. (1991) J Biol Chem 266, 16232-16237. 
22. Traxler, B. A. & Minkley, E. G., Jr. (1988) J Mol Biol 204, 205-209. 
23. Lahue, E. E. & Matson, S. W. (1988) J Biol Chem 263, 3208-3215. 
24. Schroder, G. & Lanka, E. (2005) Plasmid 54, 1-25. 
25. Lawley, T. D., Klimke, W. A., Gubbins, M. J., & Frost, L. S. (2003) FEMS 
Microbiol Lett 224, 1-15. 
26. Matson, S. W., Sampson, J. K., & Byrd, D. R. (2001) J Biol Chem 276, 
2372-2379. 
27. Byrd, D. R., Sampson, J. K., Ragonese, H. M., & Matson, S. W. (2002) J 
Biol Chem 277, 42645-42653. 
28. Traxler, B. A. & Minkley, E. G., Jr. (1987) J Bacteriol 169, 3251-3259. 
29. Scherzinger, E., Lurz, R., Otto, S., & Dobrinski, B. (1992) Nucleic Acids 
Res 20, 41-48. 
30. Pansegrau, W., Ziegelin, G., & Lanka, E. (1990) J Biol Chem 265, 10637-
10644. 
31. Pansegrau, W., Schroder, W., & Lanka, E. (1994) J Biol Chem 269, 2782-
2789. 
32. Furuya, N., Nisioka, T., & Komano, T. (1991) J Bacteriol 173, 2231-2237. 
33. Young, C. & Nester, E. W. (1988) J Bacteriol 170, 3367-3374. 
34. Srinivas, P., Kilic, A. O., & Vijayakumar, M. N. (1997) Plasmid 37, 42-50. 
35. Paterson, E. S., More, M. I., Pillay, G., Cellini, C., Woodgate, R., Walker, 
G. C., Iyer, V. N., & Winans, S. C. (1999) J Bacteriol 181, 2572-2583. 
36. Llosa, M., Bolland, S., & de la Cruz, F. (1994) J Mol Biol 235, 448-464. 
37. Greated, A., Lambertsen, L., Williams, P. A., & Thomas, C. M. (2002) 
Environ Microbiol 4, 856-871. 
38. Boer, R., Russi, S., Guasch, A., Lucas, M., Blanco, A. G., Perez-Luque, 
R., Coll, M., & de la Cruz, F. (2006) J Mol Biol 358, 857-869. 
63 
39. Larkin, C., Datta, S., Harley, M. J., Anderson, B. J., Ebie, A., Hargreaves, 
V., & Schildbach, J. F. (2005) Structure (Camb) 13, 1533-1544. 
40. Guasch, A., Lucas, M., Moncalian, G., Cabezas, M., Perez-Luque, R., 
Gomis-Ruth, F. X., de la Cruz, F., & Coll, M. (2003) Nat Struct Biol 10, 
1002-1010. 
41. Datta, S., Larkin, C., & Schildbach, J. F. (2003) Structure (Camb) 11, 
1369-1379. 
42. Grandoso, G., Avila, P., Cayon, A., Hernando, M. A., Llosa, M., & de la 
Cruz, F. (2000) J Mol Biol 295, 1163-1172. 
43. Dressler, D. (1970) Proc Natl Acad Sci U S A 67, 1934-1942. 
44. Erickson, M. J. & Meyer, R. J. (1993) Mol Microbiol 7, 289-298. 
45. Pansegrau, W. & Lanka, E. (1996) J Biol Chem 271, 13068-13076. 
46. Furuya, N. & Komano, T. (2003) J Bacteriol 185, 3871-3877. 
47. Draper, O., Cesar, C. E., Machon, C., de la Cruz, F., & Llosa, M. (2005) 
Proc Natl Acad Sci U S A 102, 16385-16390. 
48. Llosa, M., Bolland, S., Grandoso, G., & de la Cruz, F. (1994) J Bacteriol 
176, 3210-3217. 
49. Parker, C., Zhang, X. L., Henderson, D., Becker, E., & Meyer, R. (2002) 
Plasmid 48, 186-192. 
50. Pansegrau, W., Balzer, D., Kruft, V., Lurz, R., & Lanka, E. (1990) Proc 
Natl Acad Sci U S A 87, 6555-6559. 
51. Harding, M. M. (2004) Acta Crystallogr D Biol Crystallogr 60, 849-859. 
52. Matson, S. W. & Ragonese, H. (2005) J Bacteriol 187, 697-706. 
53. Bachmann, B. J., Low, K. B., & Taylor, A. L. (1976) Bacteriol Rev 40, 116-
167. 
54. Smirnova, I. N., Baykov, A. A., & Avaeva, S. M. (1986) FEBS Lett 206, 
121-124. 
55. Taylor, J. S. (1981) J Biol Chem 256, 9793-9795. 
56. Tomaszek, T. A., Jr. & Schuster, S. M. (1986) J Biol Chem 261, 2264-
2269. 
64 
57. Yount, R. G., Babcock, D., Ballantyne, W., & Ojala, D. (1971) 
Biochemistry 10, 2484-2489. 
58. Russell, R. G. (2006) Ann N Y Acad Sci 1068, 367-401. 
59. Brody, K. R., Hosain, P., Spencer, R. P., Hosain, F., & Wagner, H. N. 
(1976) Br J Radiol 49, 267-269. 
60. Huckell, V. F., Lyster, D. M., Morrison, R. T., & Cooper, J. A. (1985) Clin 
Nucl Med 10, 455-462. 
61. Wodnicka, M., Guarino, R. D., Hemperly, J. J., Timmins, M. R., Stitt, D., & 
Pitner, J. B. (2000) J Biomol Screen 5, 141-152. 
62. Ahmed, A. M., Kawamoto, H., Inouye, K., Hashiwata, Y., Sakaki, M., 
Seno, M., & Shimamoto, T. (2005) J Med Microbiol 54, 867-872. 
63. Tosini, F., Visca, P., Luzzi, I., Dionisi, A. M., Pezzella, C., Petrucca, A., & 
Carattoli, A. (1998) Antimicrob Agents Chemother 42, 3053-3058. 
64. Wei, Z. Q., Chen, Y. G., Yu, Y. S., Lu, W. X., & Li, L. J. (2005) J Med 
Microbiol 54, 885-888. 
65. Villikka, K., Perttunen, K., Rosnell, J., Ikavalko, H., Vaho, H., & Pylkkanen, 
L. (2002) Bone 31, 418-421. 
66. Recker, R. R. & Saville, P. D. (1973) Toxicol Appl Pharmacol 24, 580-589. 
67. Collaborative Computing Project, N. (1994) Acta Crystallographica D 50, 
760-763. 
68. Jones, T., Zou, J., Cowan, S., & Kjeldgaard, M. (1991) Acta 
Crystallographica A 47, 110-119. 
69. Read, R. J. (1986) Acta Crystallographica Section A 42, 140-149. 
70. Brunger, A. (1998) Acta Crystallographica D 54, 905-921. 
71. DeLano, W. L. (2002)  (DeLano Scientific, San Carlos, CA). 
72. Sherman, J. A. & Matson, S. W. (1994) J Biol Chem 269, 26220-26226. 
73. Stern, J. C. & Schildbach, J. F. (2001) Biochemistry 40, 11586-11595. 
74. Burnham, K. P. & Anderson, D. R. (1998) Model Selection and Inference 
(Springer-Verlag, New York, NY). 
75. Cornish-Bowden, A. & Eisenthal, R. (1974) Biochem J 139, 721-730. 
65 
76. Cornish-Bowden, A. & Eisenthal, R. (1978) Biochim Biophys Acta 523, 
268-272. 
77. Eisenthal, R. & Cornish-Bowden, A. (1974) Biochem J 139, 715-720. 
78. Willemoes, M., Hove-Jensen, B., & Larsen, S. (2000) J Biol Chem 275, 
35408-35412. 
66 
 
 
 
 
3 Further Relaxase Inhibition: Expanded Library, R100, 
& in vivo Assays 
Bacterial conjugation is the primary process by which antibiotic resistance genes 
spread between bacterial strains, resulting in multi-drug resistance. Relaxases 
utilize covalent phosphotyrosine intermediates to create site- and strand-specific 
single stranded DNA nicks that initiate and terminate conjugative transfer. Multi-
tyrosine relaxases can accommodate two simultaneous phosphotyrosine 
intermediates. We have recently shown that bisphosphonate compounds mimic 
dual-phosphotyrosine intermediates and inhibit F plasmid TraI relaxase activities 
in vitro, inhibit plasmid transfer, and selectively kill F+ cells.  Here we extend 
selective bisphosphonate killing to the clinical resistance-bearing F relative R100. 
We also expand our inhibitor library to include orders-of-magnitude more potent 
and selective poly-acid compounds. In gnotobiotic mice, we show that TraI 
inhibitors clodronate and etidronate – clinically approved bone loss treatments – 
cause a significant drop in F+ load through reduction of equilibrium F+ fractions 
and overall gut bacterial load. These results support the contention that 
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conjugative relaxase inhibition is a novel antimicrobial approach that selectively 
targets bacteria capable of sharing antibiotic resistance. 
 
3.1 Introduction 
The horizontal genetic transfer within and between bacterial strains are 
mediated by conjugative genetic elements, including those the transfer of 
pathogenicity factors such as antibiotic resistance (reviewed (1, 2)). Conjugative 
DNA transfer was first described by Lederberg and Tatum in 1946 for the 
Escherichia coli F plasmid (3). Antibiotic resistance is rapidly acquired via 
conjugative DNA transfer in clinical settings (reviewed (4)). Indeed, DNA 
conjugation generated all three documented instances of vancomycin resistant 
Staphylococcus aureus in the United States (5-9). Inhibition of conjugation of 
DNA conjugation or selectively killing bacteria capable of conjugation may 
prevent the generation and spread of multi-drug resistance in clinical settings.  
 
We have recently described the selective inhibition of a DNA relaxase, the 
keystone enzyme of each conjugative system (10-12). Conjugative relaxases 
initiate DNA transfer with a site and strand specific nick in the transferred strand 
(T-strand) at the origin of transfer (oriT). This results in a covalent 5’-
phosphotyrosine intermediate (7, 10, 13-16). The nicked T-strand is transferred 
from the donor cell to the recipient cell via a Type IV secretion system-mediated 
intercellular junction (reviewed (7, 17, 18)). Transfer is complete when the 
relaxase reverses the phosphotyrosine linkage, ligating and releasing the T-
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strand. Many conjugative relaxases use one catalytic tyrosine (e.g., relaxases 
from plasmid incompatibility groups IncQ, IncP, and IncI (19-22), the 
Agrobacterium inter-kindom transfer system (23), and certain conjugative 
transposons (24)). In the F plasmid system, however, the relaxase, is the N-
terminal domain of a multifunctional protein, TraI (15, 16, 25-27). F TraI-like 
relaxases (e.g., plasmids of incompatibility groups IncF, IncN, IncW, and 
Pseudomonas IncP9 (27-30), including many resistance-bearing plasmids) have 
an N-terminal constellation of two to five tyrosines nearby a chelated metal ion 
(31-35). Two catalytic tyrosines and a metal ion are require for maximum 
cleavage, ligation and transfer activity (36). Additional tyrosines may be used to 
resolve a replication intermediate created when replication begins at the original 
nick site during conjugation. This could be accomplished by creating a second 
nick, resulting in two simultaneous phosphotyrosine linkages. Indeed, a dual-
phosphotyrosine intermediate has been trapped with suicide oligonucleotides 
(37).  We previously predicted that this dual-phosphotyrosine intermediate would 
exist and used it as a starting place for inhibitor design (35). 
 
Past studies indicated that some polycyclic chemicals, antibiotics and 
crude extracts inhibit of conjugation (38-44). However, these effects are mainly 
attributable to inhibition of bacterial growth or DNA synthesis and are 
independent of conjugation or conjugative transfer capability (45-48). Previously, 
we reported that several bisphosphonates both inhibit conjugation and selectively 
kill cells harboring the F plasmid (35). In this study, we expand our inhibitor 
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library beyond bisphosphonates to other bis-acids. We also demonstrate 
selective killing of cells with an F-related clinical resistance plasmid, R100. 
Perhaps most significantly, we show that two clinically approved 
bisphosphonates, etidronate and clodronate, eliminate up to 95% of F+ 
Escherichia coli in a mammalian model at the standard human dose per unit 
body mass. 
 
3.2 Results 
3.2.1 In cell inhibitor library 
We employ a fluorescence-based 96-well cell-enumeration assay to 
determine the conjugation inhibition and selective F+ killing efficacy of a library of 
compounds. Seven bisphosphonate compounds were previously tested on the F 
plasmid system by this method (35), of which six were selective killers of F+ E. 
coli and five of which were inhibitors of conjugation with EC50 values of <10 µM. 
We now expand this library with an additional 19 poly-acids, a mixture of 
phosphonate, carboxylate, sulfonate, and arsonate compounds. (Figure 1) Each 
was assayed for activity versus F+ and F- E. coli and against F plasmid 
conjugation. The dose-response curves were often complex, occasionally 
multiphasic, with various inflections and non-zero plateaus. Thus, half-effective 
concentrations (EC50s) are concentrations at which the process or population in 
question is reduced to 50% of uninhibited controls, with no implication of EC50 
identity with any inflection point and no bearing on the relative levels of any 
plateaus or baselines.  
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At the 50% effective level, eight of these compounds were potent selective 
killers of F+ cells (EC50s versus F+ <2 µM and versus F- >1 mM). (Table 1) The 
most potent and selective of these was SCS, with an anti-F+ EC50 of 4.8 nM, and 
an F+-versus-F- EC50 ratio of 2.1x106. Nine of the compounds were effective 
inhibitors of conjugation, with EC50s <6 µM. The most potent of these was 
SPhCOO, with an EC50 versus conjugation of 4.8 nM (3.6x107 times lower than 
its EC50 versus F- cells). The method for estimating conjugation uses 
transconjugant counts and does not distinguish between killing of 
transconjugants and inhibition of the conjugative process. However, four of the 
compounds (citrate, SCYSCO, PCNCPM, and PCNCPE) exhibit little toxicity but 
permit the formation of few transconjugants, implying potent inhibition of 
conjugation to a degree unobserved in the previous study (35). Indeed, the 
highest conjugation-versus-F+ EC50 ratio of the previous study was for 
clodronate at 78, while citrate has a ratio of 7.5x106. Five compounds (SCS, 
SCCS, SBENCO, PCCCOO, and SPhCOO) were selective against both donor 
cells and conjugation. Three of the compounds (SNS, SCCCS, and malonate) 
were ineffective both at killing F+ cells and at inhibiting conjugation. Four of the 
compounds (ABENA, SBENS, SCCOO, and PCCOO) were very potent killers of 
F+ cells and inhibitors of conjugation, but also evidenced toxicity versus F- cells. 
Thus, we have now identified four additional relaxase inhibitors with better than 
20 µM EC50 versus conjugative DNA transfer, three with comparable effect on F+ 
cell survival, and nine with such effects on both. 
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3.2.2 Lethality with a clinical resistance plasmid 
Five compounds from the expanded library, SCS, CIT, PNP, PBENP, and 
ETIDRO, were tested against MC4100 E. coli cells bearing resistance plasmid 
R100-1 (R100-1+ cells). PNP, PBENP, and ETIDRO had potent EC50 values 
(less than 20 µM) for killing R100-1+ cells, PNP and ETIDRO less than 100 nM. 
SCS and CIT exhibited no anti-R100-1+ effects. CIT had shown little anti-F+ 
effect, SCS had been a potent selective killer of F+ cells. 
 
3.2.3 Decrease in total bacterial load and F+ fraction 
C57 BI/6J mice were administered by gavage a once daily 200 µl dose of 
100 µg/kg etidronate or 180 µg/kg clodronate. These mice  showed no 
statistically significant changes in terms of total bacterial load or of F+ fraction in 
fecal matter, relative to the control cohort (16 day treatment period).  
 
The dosage was raised and the delivery method was adjusted to allow for 
more constant gut concentrations. Sample group mice were provided drinking 
water with 20 mg/ml etidronate (n=3) or clodronate (n=4). Given the approximate 
daily water consumption of these mice, these concentrations roughly correspond 
to one tenth of the maximum approved human dose per unit body mass. Within 7 
days, the total fecal bacterial load did not change significantly, but for mice 
treated either clodronate or etidronate, the F+ fraction of remaining bacteria fell to 
around 60%. Over the next two days, the F+ fraction remained unchanged for 
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clodronate-treated mice, and rebounded to control levels for etidronate-treated 
mice. (Figure 3) 
 
The original mice were shuffled and 10 new mice were added, doubling 
cohort sizes. After confirmed infection and bacterial load stabilization, sample 
cohorts were provided drinking water with 200 mg/ml etidronate (n=6) or 
clodronate (n=8), roughly equivalent to the maximum approved human dose per 
unit body mass. (Figure 4) One cage of mice (3 mice) did not respond to 
etidronate treatment. This cage is neglected for all future etidronate calculations 
(new n=3). Within 5 days, the total fecal bacterial load, corrected for differences 
in initial loads and normalized versus control, dropped to 14 ± 3% and 21 ± 4% 
(s.e.m.), for mice treated with etidronate or clodronate respectively. The loads 
varied somewhat over the remaining ten days of treatment, with mean values of 
18 ± 6% and 28 ± 6% (s.d.; neglecting an anomalous spike in bacterial load on 
the eighth day of treatment, not shown). Likewise, the F+ fraction of remaining 
bacteria fell to 29 ± 7% and 21 ± 3% (s.e.m.) in the first 5 days, and stabilized at 
48 ± 17% and 33 ± 9% (s.d.). This led to an initial dip in F+ loads to 5 ± 2% (s.d.) 
with both drugs, and equilibrium F+ loads of 18 ± 17% and 18 ± 14% (s.d.), for 
mice treated with etidronate or clodronate respectively.  
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3.3 Discussion 
3.3.1 Qualitative SAR analysis 
The complex nature of many of the in cell dose response curves 
complicates analysis of structure-activity relationships (SAR). As stated, curves 
occasionally multiphasic, with various inflections and non-zero plateaus. Some of 
these, especially for F+ survival, may be explained as combinations of inhibitory 
effects and pH effects. For example, the dose response of F+ cells against PNP 
has a sigmoid curve with a minimum of ~35% and inflection at ~100 nM, until the 
PNP concentration exceeds 4 mM and overcomes the buffering capacity of the 
medium. The survival curve then drops to <1% by 100 mM PNP. Multiphasic 
transconjugant curves generally correspond to multiphasic donor or recipient 
survival curves. 
Our primary SAR analysis is based on effective concentrations from 
normalized donor, transconjugant, and recipient counts cell dose response 
curves (ECXs, where X = percent decrease versus control; e.g. an EC75 is the 
inhibitor concentration resulting in 25% of the control value). The basic TraI 
inhibitor framework is a poly-acid composed of four parts: two acid moieties, a 
bridge between the acids, and a sidechain or sidechains on the bridge. In our 
previous study, all poly-acid moieties were phosphonic, bridge lengths varied 
between 1-4 atoms, and side chains ranged from one hydrogen (PNP) to a long 
amidated chain (NERDRO). PBENP was unique as the one example where the 
sidechain cycled with the bridge and as the one example where the acidic 
oxygen atoms were blocked by methoxy moieties. This study expands the library 
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to include carboxylate, sulfonate, and arsonate poly-acids, as well as mixed-
moiety poly-acids (e.g. PCCOO). Among compounds tested in cell, overall 
charges range from 0 (PBENP) to -4 (e.g. PCP). 
 
In general, inclusion of a benzene ring, either cyclized with the bridge or 
on a short sidechain, increased potency versus all cell types, but most especially 
versus recipient cells (at the EC50 level, compare SBENS to SCCS and 
SPhCOO to SCCOO). The differing selectivities of ABENA and PBENP suggest 
that methoxylation of at least highly charged acid moieties can protect recipient 
cells from some lethal effects. Every potent compound with a bridge length >2 
has at least one hydrogen-bonder on the bridge or sidechain (counter example: 
SCCCS). This may be due to increased hydrophylicity or perhaps through direct 
interaction of hydroxyl with the magnesium ion, analogous to the interaction of 
the 3’ hydroxyl of the scissile thymidine, as seen in previous structures (35). 
 
All four compounds assayed in this study that had three-atom bridges and 
multi-atom sidechains (PCNCPM, PCNCPE, citrate, and SCYSCO) are potent 
transconjugation inhibitors and ineffective at donor killing at the EC50 level. Each 
of these has hydrogen bond donors and acceptors on its sidechain. The three of 
these with hydroxylated sidechains (PCNCPM, PCNCPE, citrate, but not 
SCYSCO) are potent at the EC50 level. These compounds were chosen for their 
presumed ability to chelate the active site magnesium at all three available 
octahedral coordination sites. Six compounds were chosen to fulfill these 
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requirements in our previous study: ETIDRO, CLODRO, PAMDRO, NERDRO, 
PGLYP, and PCNCP2. ETIDRO and CLODRO proved to be potent both in vitro 
and in cell. With EC50 ratios of 30 and 78, respectively, ETIDRO and CLODRO 
were also the most selective among previously tested inhibitors for conjugation 
inhibition over donor cell killing. That said, conjugation inhibition selectivity of 
ETIDRO and CLODRO pale in comparison with PCNCPM, PCNCPE, or citrate 
(transfer versus donor killing EC50 ratios of 2500, 15,000, and 750,000, 
respectively). The other four previous compounds, PAMDRO, NERDRO, PGLYP, 
and PCNCP2, had charged and flexible sidechains (at least two free-rotating 
bonds), and all failed in a coarse screen as in vitro TraI inhibitors. We 
hypothesized that the charged character of the sidechains was causing some 
unfavorable interaction in the active site. This hypothesis was disproved by 
citrate. Citrate was the only compound with a charged sidechain in this study, 
and it was one of the most potent and selective inhibitors of tranconjugation 
reported herein. We thus conclude that flexible sidechains preclude TraI 
inhibition, at least on poly-acids with 3-atom bridges. 3-atom bridges may be the 
optimal poly-acid tether, allowing flexible poly-acid and hydroxyl positioning on 
the active site magnesium coordination sites. Compounds with longer or shorter 
bridges were somewhat effective at the EC50 level, but were selective for donor 
killing over conjugation inhibition (e.g. SGLUTS and SCOCOS).  
 
At the EC75 level, ETIDRO, citrate, SCOCOS, ABENA, SBENS, SCCOO, 
and PCCOO are the only potent inhibitors thus far assayed. Only SCOCOS, 
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ABENA, and SCCOO have EC80 values below the 20 µM potency cutoff, all for 
donor cell killing, though ETIDRO, citrate, and SBENS only narrowly miss, with 
EC80s of 30-50 µM. ABENA qualifies as potent at the EC85 level (9.9 µM) with 
only SCCOO close (29 µM). Only ABENA has EC95+ values in the micromolar 
range, and only ABENA has an EC99 in the single-digit millimolar range (~3 
mM), corresponding to less than 1 µg/ml. 
 
The success of poly-acids with hyrdoxylated or benzylated bridges, in 
every metric employed, is unsurprising given their resemblance to our idealized 
pharmacophore. The aromatic rings were intended to interact with either the 
aliphatic region of the lysine 265 sidechain or with the sidechain of one of the 
catalytic tyrosines. The poly-acid moieties were intended to fill the octahedral 
coordination sites of the active site magnesium ion. The most interesting new 
result is the conjugative inhibition of citrate, given its physiologically innocuous 
nature. Future studies will focus on citrate and derivatives or analogues thereof, 
and on poly-acids with various aromatic rings. We are particularly interested in 
investigating compounds that combine aromatic rings with citrate-like 
hydroxylated bridges in hopes of finding compounds with the selectivity of citrate 
with the potency of the aromatics. 
 
3.3.2 Bisphosphonates in other systems 
Five compounds from the expanded library, SCS, CIT, PNP, PBENP, and 
ETIDRO, were tested against cells bearing resistance plasmid R100-1, a 
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derepressed derivative of R100, a close relative of the F plasmid. All of these 
compounds, except CIT, had exhibited potent EC50 values (less than 20 µM) for 
killing F+ cells. CIT had little anti-F+ effect, with an EC50 in the hundreds-to-
thousands of micromolar range. PNP, PBENP, and ETIDRO displayed potent 
EC50 ranges when tested against R100-1+ cells. The differences in EC50 values 
between F+ and R100-1+ show that there are strain and plasmid specific effects 
that merit further investigation. 
 
R100 is the first clinical resistance plasmid for which selective 
bisphosphonate lethality has been observed. This extends the antimicrobial 
activity of simple bisphosphonates beyond the F plasmid model system. R100 is 
a close relative of the F plasmid, with approximately 98% identity between 
transfer regions. Studies with more distantly related conjugative systems are 
ongoing. 
 
In the mouse gut, we have shown the efficacy of ETIDRO and CLODRO 
for reducing the F+ bacterial fraction and for reducing the overall bacterial load 
when F+ cells are present. ETIDRO and CLODRO at 200 mg/L, approximately 
the current approved human dose (by body mass and average daily mouse water 
consumption), reduced the F+ E. coli load by 95±2.3% by the first timepoint. For 
the F plasmid system, a low dose of bisphosphonates appears to reduce the 
potential for the transfer of antibiotic resistance in the mammalian gut twenty-fold. 
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3.4 Materials and Methods 
3.4.1 Bacterial strains and plasmids 
F-plasmid donor cells (JS10) and recipient cells (JS4) were provided by 
the laboratory of Steve Matson (University of North Carolina at Chapel Hill, USA) 
and have been described (25). Briefly, JS10 Escherichia coli contain the pOX38T 
tetracycline resistance encoding min-F plasmid. JS4 E. coli have genomic 
streptomycin resistance. Plasmids R100 and R100-1 (in MC4100 and BL21 E. 
coli cells, respectively) were provided by the laboratory of Laura Frost (University 
of Alberta, Canada). 
 
3.4.2 Fluorescent Mating & Toxicity, selection in liquid media 
Inhibitor candidates were purchased from Fisher Scientific or Sigma-
Aldrich (especially Sigma-Aldrich's Rare Chemical Library). Growth, mating and 
preparation were proceeded as previously described (35) (based originally on 
(25)). Briefly, saturated, antibiotic-selected overnight cultures of both donor and 
recipient strains were pelleted, suspended in fresh media without antibiotics, 
diluted 1:50 and grown at 37 ºC to an OD600 ~0.6.  Donors, recipients and 
inhibitors were mixed in a 9:81:10 ratio, respectively. Final inhibitor 
concentrations ranged from low picomolar to high millimolar. Selection of donors, 
recipients and transconjugants were performed in Oxygen Biosensor™ 96-well 
plates (BD Biosciences). Cell concentrations were quantified on a Pherastar 
fluorescent plate reader (BMG) via fluorescent doubling-time analysis as 
previously described (49). 
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3.4.3 Care and handling of gnotobiotic mice 
Three cohorts (I-III) of germfree inbred C57 BI/6J mice (aged 6 months) 
supplied by the Gnotobiotic Core at The University of North Carolina at Chapel 
Hill under the auspices of the Center for Gastrointestinal Biology and Disease 
(CGIBD) Gnotobiotic Core. Mice were inoculated with JS10 donor E. coli cells via 
direct application of pure cultures to mouth and anus and inoculation of food, or 
by cohabitation with mice thus infected. Mice were maintained in flexible plastic 
isolators at the CGIBD. Fecal bacterial populations were assayed for strain purity 
via MacConkey plates. Only dark colonies of lactic acid-metabolizing bacteria, 
such as E. coli, were observed on MacConkey plates. The morphology of gram 
stained cells from fecal samples matched that of cells from the pure JS10 
inoculum. Antibiotic selection on Luria-Bertani agar (with or without 5 µg/ml of 
tetracycline and incubated at 37°C under aerobic conditions) was used to assay 
fecal samples for plasmid content. All mice were confirmed to have a numerically 
stable, 100% tetracycline resistant E. coli population within two weeks of 
inoculation (within nine days for all but on mouse). All experimental procedures 
were approved by the University of North Carolina Animal Use and Care 
Committee. 
 
3.4.4 Plasmid fraction and bacterial load 
After the first 10 mice were confirmed to have stable bacterial loads, 
sample group mice were administered a once daily 200 µl gavage of 100 µg/kg 
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etidronate (cohort II, n=3) or 180 µg/kg disodium clodronate (cohort III, n=4) in 
sterile phosphate buffered saline (PBS). Fecal samples were assayed via 
antibiotic selection on Luria-Bertani agar every other day for the duration of the 
treatment period (16 days). No statistically significant changes were observed in 
terms of total bacterial load or of F+ fraction, relative to the control (cohort I, n=3). 
 
After a two week rest period, in which bacterial loads and F+ fractions 
remained constant, the delivery method and dosage were adjusted to allow for 
more constant gut concentrations and the mice were randomly reassigned to 
cohorts. Sample group mice were provided drinking water with 20 µg/ml 
etidronate (n=3) or disodium clodronate (n=4), approximately one tenth of the 
maximum approved human dose per unit body mass. Fecal samples were diluted 
105-fold and then enumerated via the Most Probable Number dilution method 
(50) as estimated based on a spreadsheet-based calculator from the United 
States Food and Drug Administration Online Bacteriological Analytical Manual 
(51) . 
 
After a one week rest period, 10 additional mice were added to the cages 
and the mice shuffled to create new cohorts of double the original size. After 10 
days, all mice exhibited stable infection and 100% F+ fraction with no evidence of 
extraneous bacterial contamination. Sample group mice were then provided 
drinking water with 200 mg/ml etidronate (n=6) or disodium clodronate (n=8), 
approximately equivalent to the maximum approved human dose per unit body 
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mass. This treatment lasted for 15 days, during which fecal bacterial content was 
assayed three times. At the end of the experiment, the mice were humanely 
destroyed. 
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3.5 Figure Legends 
Table 1.  EC50s from relative cell counts.  
Colors indicate potency: orange > 20 µM; yellow = 1-20 µM; green = 10-999 nM; 
blue < 10 nM. Median (med.) values are calculated from averaged cell count 
curves, high and low values from ±1 standard deviation curves. 
 
Figure 1.  Compounds tested for this and previous studies (35).  
Characters in parentheses are the abbreviations for each compound. 
 
Figure 2.  F+ fraction during 0.1x bisphosphonate treatment. 
The fraction of F+ JS10 E. coli cells in the mouse gut decreases over time during 
treatment with either 20 mg/L ETIDRO (red bars; s.d., n = 3) or CLODRO 
(orange bars; s.d., n = 4), approximately one tenth the human approved dose per 
unit body mass, given the average volume of water consumed daily per mouse. 
Yellow bars represent the control group, which received vehicle only (s.d., n = 3). 
 
Figure 3.  F+ fraction and bacterial loads during 1x bisphosphonate 
treatment. 
A. The fraction of F+ JS10 E. coli cells in the mouse gut decreases over time 
during treatment with either 200 mg/L ETIDRO (red bars; s.d., n = 3) or 
CLODRO (orange bars; s.d., n = 8), approximately the human approved dose 
per unit body mass. Yellow bars represent the control group, which received 
vehicle only (s.d., n = 6). 
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B. E. coli bacterial loads in the mouse gut during 1x ETIDRO (red bars; s.d., n = 
3) or CLODRO (orange bars; s.d., n = 8), relative to control mice and 
corrected for differences in initial loads. 
F+ E. coli bacterial loads in the mouse gut during 1x ETIDRO (red bars; s.d., n = 
3) or CLODRO (orange bars; s.d., n = 8), relative to control mice and corrected 
for differences in initial loads. 
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Table 3-1 EC50s from relative cell count 
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Figure 3-1 Compounds tested for this and previous studies 
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Figure 3-2 F+ fraction during 0.1x bisphosphonate treatment 
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Figure 3-3 F+ fraction and bacterial loads during 1x bisphosphonate 
treatment 
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4 Advent of TraI: Phylogenetics of Relaxase Evolution 
Antibiotic resistance genes spread between bacterial strains primarily 
through bacterial conjugation. This can create multi-drug resistant bacterial 
strains. Relaxases create site- and strand-specific single stranded DNA nicks, via 
covalent phosphotyrosine intermediates, which initiate and terminate conjugative 
transfer. We use phylogenetic analyses of bacterial relaxases to show the origins 
of these clinically important enzymes and to support our previously proposal that 
multi-tyrosine relaxases resolve the products of concomitant DNA replication. 
 
4.1 Introduction 
Antibiotic resistance genes and other virulence factors are spread within 
and between bacterial strains through horizontal gene transfer (reviewed (1)). 
Horizontal transfer in bacteria is accomplished primarily through conjugation 
(reviewed (2)), as first described for the Escherichia coli F plasmid by Lederberg 
and Tatum in 1946 (3). In clinical settings, antibiotic resistance is acquired with a 
rapidity that is critically dependent on conjugative DNA transfer (reviewed (4)), as 
was the case for all documented instances of vancomycin resistant 
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Staphylococcus aureus in the United States (5-9).  Either the inhibition of 
conjugation or the selective killing of conjugation capable bacteria in clinical 
settings would be a highly desirable suppressive of the generation and spread of 
multi-drug resistance.  
 
The details of the diverse Mob family relaxase mechanisms are poorly 
understood. Some relaxases possess one catalytic tyrosine residue (TraA and 
VirD2 of Rhizobia and Agrobacteria pTi plasmids; TraI of plasmid RP4 IncQ) 
while others have a constellation of conserved tyrosines (TraA of Corynebacteria 
plasmids; TrwC of plasmid R388 IncW; TraI of plasmid R100 IncF plasmids). The 
IncF/W constellation of two tyrosine pairs follows a pattern of Yy-X3-26-YY, where 
‘y’ denotes either a tyrosine or a  phenylalanine in some IncW relaxases (10). 
The tyrosine pairs may be responsible for multiple transesterifications similar to 
the rolling-circle model described for bacteriophage phi X174 (11-13). During the 
nicking (transesterification) reaction, a catalytic tyrosine forms a covalent bond 
with a phosphate of the nicked strand (14, 15). Mutant data with R388 TrwC 
show that all four tyrosines show varying degrees of capability for creating the 
initial nick (16). We have suggested that the second tyrosine set is responsible - 
via a dual phosphotyrosine intermediate - for resolution of a new nick site created 
by concurrent replication (17). Though this intermediate was recently observed 
(18), we undertook a phylogenetic analysis of bacterial relaxase sequences both 
to find the origins of multi-tyrosine relaxases and in the hope that the order of 
evolutionary innovations would either support or refute our hypothesis that 
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multiple tyrosines are needed for the resolution of concurrently replicated nick 
sites.  
 
4.2 Results 
4.2.1 Alignment of diverse bacterial relaxases 
Homology searches, based on seed sequences for one single-tyrosine 
relaxase (plasmid R64 NikB) and one multi-tyrosine relaxase (Brevibacterium 
linens BL2 TraA), returned, after manual curation, over 130 relaxases 
sequences. These included sequences from every major bacterial plasmid 
incompatibility class, and chromosome and transposons sequences. Sequences 
were recovered from soil-, deep sea-, animal- and plant-associated gram positive 
and gram negative strains, including plant, wildlife, livestock, and human 
pathogens. 
 
4.2.2 Relaxase phylogenetics 
Assuming that the outgroup for each tree (Figure 1) was the TraI relaxase 
of IncP plasmid R751, single-tyrosine relaxases appear to be basal. Multi-
tyrosine active sites appear to be monophyletic, with the Streptomyces relaxases 
pFP11.6c and pFP1.1 as the basal taxa. The multi-tyrosine clade is a sister 
group to the a cluster of IncQ-like relaxases, including the IncQ-like TraA 
relaxases of Agrobacterium virulence plasmids and relaxases from true IncQ 
plasmids, such as MobA of plasmid RSF1010. This makes the IncQ-like 
relaxases polyphyletic, with relaxases from IncQ-like plasmids pTC-F14, pTC-
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FC2, pRAS3.1 and pRAS3.2 more closely related to IncP-6/G/U, IncL/M, and 
IncI1 relaxases than to true IncQ relaxases. Relaxases with carboxy-terminal 
helicase domains make up a paraphyletic group composed of the 
Legionella/Rhizobial TraA clade and the multi-tyrosine clade, but excluding the 
true IncQ relaxases and their closest relatives. 
 
Treating Gram stain ability of the host cell as a character state, the most 
parsimonious tree, rooted with R751 TraI, has seven state changes and suggests 
a gram positive host for the last common ancestor of IncP-like and multi-tyrosine 
relaxases. The closest homologue to the relaxase-fused helicase domains is 
RecD, part of the RecBCD complex of Gram negative bacteria. Thus the last 
common ancestor of all helicase-fused relaxases must have come from a Gram 
negative cell. The most parsimonius tree that can incorporate this knowledge has 
eight state changes and also implies a Gram positive last common ancestor. The 
chosen root is from a gram positive source, as are the basal groups for both the 
muti-tyrosine clade and the helicase/IncQ clade. 
 
4.2.3 Motif I duplication 
Streptomyces relaxases pFP11.6c and pFP1.1 bear direct repeats near 
their amino-termini, as detected by European Molecular Biology Laboratory - 
European Bioinformatics Institute (EMBL-EBI) online Rapid Automatic Detection 
and Alignment of Repeats (RADAR). These repeats duplicate relaxase Motif I, 
including the catalytic tyrosine. 
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4.3 Discussion 
4.3.1 Ancestral relaxase host 
 If Gram stains are taken as a two-character state, parsimony suggests 
that the common ancestor of Clade 0 (all relaxases studied herein) resided in 
Gram positive cells. The parsimony evidence for this is relatively weak, as 
several trees incorporating a Gram negative root fall short of the minimum step 
count by only one or two steps. Given the broad range of many plasmids, it may 
be just as likely that the last common ancestor resided in both Gram positive and 
Gram negative strains.  
 
Relaxases Clades 8 and 6 have fused carboxyl-terminal helicase 
domains. The closest non-relaxase relative of these helicases is RecD, of the 
Gram negative DNA repair complex RecBCD. Thus the common ancestor of 
Clades 8 and 6 must have resided in a gram negative bacterium. The distribution 
of taxa in Clade 2 also suggests that the ancestors at nodes 2, 4, 5, 6, 10, and 11 
inhabited hosts that lived either in soil, on plants or plant detritus, or both. 
 
Helicase fusion occurred at Node 4, implying helicase deletion at Node 7. 
This was unexpected and may be an artifact of maximum parsimony calculations 
using wildcard alignment gaps. Far more likely is that Clades 6 and 8 are sister 
groups that originally diverged from the IncQ MobA relaxases of Clade 7 after 
helicase fusion. 
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4.3.2 Evolution of multi-tyrosine relaxases 
Motif I bifurcation occurred through partial gene duplication after helicase 
fusion, apparently in a Streptomycete host or some other Gram positive soil 
dweller. Duplication resulted in a chain of more than thirty residues between the 
tyrosine pairs, corresponding to a loop region in structures of F TraI and R388 
TrwC (Clade 9) (17-21). Remnants of the long loop may be found in extant 
relaxases on plasmids pFP11.6c and pFP1.1, still with signs of the original 
duplication. This chain was paired down in subsequent relaxases: to 18-22 
residues in Clade 10; to 15-25 in pNAC3 TraA; and then to 3-5 in the rest of 
Clade 9 (except for one clade of mostly deep sea Vibrio relatives (22)). The rapid 
reduction of this loop may suggest an advantage to stiffening the loop or clearing 
residues from the active site. Stiffening  or simply shortening of the loop may aid 
in a concerted conformational change encompassing all of the tyrosines, as 
previously suggested for F TraI (17). It would be interesting to see the effects of 
insertion of a large loop in this region of F TraI or R388 TrwC, or conversely a 
loop deletion in one of the pFP relaxases. 
 
4.3.3 Multiple tyrosines and fused helicases 
Fixation of N-terminal secondary tyrosines occurred only after helicase 
fusion, which may imply an advantageous connection between helicase fusion 
and multiple tyrosines. Secondary tyrosines proximal to N-termini are common in 
Clade 7 IncQ-like relaxases and Clade 8 helicase-fused relaxases, but these 
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tyrosines are interchangeable with other residues, primarily hydrophobic 
residues. The advantage conferred by the bifurcated tyrosine constellation may 
be related to the speed of DNA unwinding and/or strand transfer. Conjugative 
helicases are among the fastest and most processive monomeric helicases 
known (approximately 1100 bp/s, from F TraI (23)). Assuming that the motive 
force for unwinding in non-helicase-fused systems is provided by the DNA 
replication machinery (approximately 300 bp/s, from phage T7 replication (24)),  
plasmid transfer for helicase-fused systems may proceed 3-4 times faster. For 
conjugation, faster unwinding results in faster transfer, which in turn results in 
fewer partial transfers due to mating pair shearing. Selective advantage results 
because more complete transfers mean greater proliferation. 
 
Faster unwinding also has disadvantages. If replication begins at the nick 
site during transfer, then a second nick site is formed and must be resolved by a 
second nicking event before transfer termination. One obvious solution is to use 
a second relaxase to resolve the new nick site, and this may be the solution used 
in single-tyrosine systems. However, rapid unwinding and transfer (e.g. ~ 90 
seconds for the F plasmid) allows little time for resolution of the new nick site. We 
have suggested that the second tyrosine set is responsible for resolution of a 
new nick site via a dual phosphotyrosine intermediate (17). This intermediate 
was recently trapped and observed using suicide oligonucleotides (18). The 
same study showed that the second nick was dependent upon the formation of a 
specific secondary DNA structure just upstream of the nick site, which the 
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relaxase can recognize and bind (19). Since the relaxase domain is maintained 
proximal to the unwinding fork by the fused helicase, there is the potential for the 
relaxase to rapidly recognize and process the new nick site as it passes through 
the helicase domain. In this sense, helicase fusion was a permissive event that 
bestowed a selective advantage on fixation of secondary N-terminal tyrosines.  
 
Whatever the selective advantage gained by the combination of multiple 
tyrosines with helicase fusion, it has allowed the multi-tyrosine relaxases to 
expand beyond the soil dwelling hosts of pFP11.6c and pFP1.1 and the plant 
pathogen niche inhabited by Clade 8 (these helicase-fused tra relaxases are 
used for interbacteria transfer, and should not be confused with vir relaxases 
from the same strains, which are responsible for transfer between bacteria and 
plants and are not discussed here (25)). This move from soil and plant dwellers 
resulted in many of resistance-bearing conjugative plasmids that plague modern 
medicine. 
 
4.4 Materials and Methods 
4.4.1 Initial homology searches 
Initial homology searches were made with Psi-BLAST (26). Single-tyrosine 
relaxase sequences were acquired with the amino acid sequence of plasmid R64 
NikB (NCBI accession BAA78021) amino-terminal region, through relaxase Motif 
III (residues 1-167) as the search target and default Psi-BLAST settings. 500 hits 
were accepted. Sequences with expectation values (E-values) higher than 1e-10 
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were culled manually and sequences lacking canonical relaxase Motifs I and III 
were rejected. All sequences with canonical relaxase Motifs I and III were 
accepted regardless of E-value. Psi-BLAST iterations 1-4 yielded sequences with 
annotated NikB, VirD2, Inc P type TraI, MobA, and Rlx. Round five yields the first 
sequence annotated TraA. The hit list was expanded to 1000 sequences. 
Iterations 6 and 7 added sequences annotated as pre, and recombinase. The hit 
list was expanded to allow 1500 sequences, but no additional sequences met E-
value or Motif criteria. The search was terminated and all sequences with E-
values of 7e-10 or less were collected. (Table 1) 
 
Multiple-tyrosine relaxase sequences were acquired with the peptide 
sequence of the Brevibacterium linens BL2 TraA (NCBI accession 
ZP_00379389) amino-terminal region, through relaxase Motif III (residues 1-174) 
as the search target and default Psi-BLAST settings. 500 hits were accepted. 
Sequences with expectation values (E-values) higher than 1e-10 were culled 
manually and sequences lacking canonical relaxase Motifs I and III were 
rejected. All sequences with canonical relaxase Motifs I and III were accepted 
regardless of E-value. Psi-BLAST iterations 1-4 yielded sequences with such 
annotations as Corynebacterium type TraA, Agrobacterium type TraA Agro, and 
IncF type TraI. Round five returned additional sequences that met E-value and 
Motif criteria. The search was terminated and all sequences with E-values of 4e-
10 or less were collected from the National Center for Biotechnology Information 
(NCBI) protein sequence database.  
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4.4.2 Semi-automated sequence annotation 
Full NCBI protein reports, in concatenated form, were parsed with a short 
custom Perl script. The parsed headers and protein sequences were entered into 
a custom Microsoft Excel 2003 spreadsheet that further parsed the Perl output 
and generated hyperlinks to each report page. The hyperlinks were used to 
access reports with ambiguous or incomplete annotation to allow manual 
annotation.  Annotation uses the following format: 
a_b_c_d y 
where 
a = gene (from NCBI report entry /gene or manual) 
b = locale (NCBI report entry /plasmid, /locus_tag, or manual) 
c = organism (NCBI report entry /organism or manual) 
d = strain note (manual notation) 
y = accession # 
Locale (b) is noted with the following formats: 
Ch_# = supposed chromosomal locus # 
Ch_  = supposed chromosomal locus unknown 
Chr# = locale chromosome # 
Where known, the organism (c) is denoted with a five letter concatenation 
of the first three letters of the genus name and the first two of the species (e.g. 
Escherichia coli is denoted as Escco). 
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4.4.3 Initial multiple sequence alignment 
Alignments were constructed in ClustalX version 1.80 (27). The initial 
alignment (250 sequences) was made as per BLAST (26) defaults (Blossum 
matrix series, gap opening/extension penalties set to 11/1).  Alignment distances 
were used to construct a Neighbor-Joining tree from the distances in the .dnd file 
generated with the alignment. The tree subjected to 10 rounds of bootstrapping 
with ClustalX (cursory: gaps allowed and no multi-substitution correction). The 
sequences were divided into clusters (Table 2) by bootstrap value, where a 
cluster was defined as a maximal set of sequences with bootstrap values greater 
then 5 (out of 10) for all intervening nodes.  
 
4.4.4 Tree building 
Alignments created in ClustalX were edited and columns with gaps 
stripped in BioEdit (28). Identical sequences were combined in DAMBE. Trees 
were constructed in ClustalX, Protpars (Bioedit), and DAMBE (29). Trees were 
bootstrapped, where applicable, in ClustalX, Phylip, and DAMBE. Branches with 
bootstrap values of less than 50 (out of 100) were culled. Trees were visualized 
in Treeview (30) and colorized in Adobe Photoshop. 
 
4.5 Special Acknowledgement 
I would like to thank Daniel Timothy Winston for writing the PubMed gene 
report initial parser script. 
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4.6 Figure Legends 
Figure 1.  Maximum parsimony phylogram of bacterial relaxases. 
This phylogram was generated from an alignment of the full amino acid 
sequences of 251 relaxases. Each n-residue gap in the alignment was assigned 
as one gap character and n-1 wildcard characters. All alignments used 
secondary structure masking based on F TraI and R388 TrwC structures. 
Important nodes are numbered for callouts in the text. Branch and title colors 
indicate Gram satin character, red meaning Gram positive, yellow for Gram 
negative, and cyan indicating cyanobacteria.  Parsimony was used to 
approximate the Gram character for ancestral nodes. All helicase-fused bacterial 
relaxases branch from nodes 6 and 8 and all multi-tyrosine relaxases from node 
6. 
 
Table 1.  ClustalX alignment input variables. 
 
Table 2.  Accession numbers and titles of relaxase sequences. 
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Figure 4-1 Maximum parsimony phylogram of bacterial relaxases 
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Table 4-1 ClustalX alignment input variables 
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Table 4-2 Accession numbers and titles of relaxase sequences 
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5 Appendix 1: Attempted Real-Time Relaxase Kinetics 
Equilibrium binding and single-time point activity data has been reported 
for F TraI (1-5) and for R388 TrwC (6-8), in the presence of various substrates, 
metal ions, mutations, and buffers . However, no steady-state kinetic assays may 
be found in the literature, leaving a hole in our understanding of relaxase 
mechanisms. Such studies are hampered by very tight substrate and product 
binding (1), inefficiencies associated with discontinuous assays, and difficulties 
and safety issues of radiolabeling. In addition, the formation of covalent 
phosphotyrosine intermediates with the enzyme prompted previous investigators 
to use high enzyme concentrations prohibitive of steady state measurements. In 
order to unravel the details of the TraI relaxase mechanism and to better 
understand reported inhibition thereof (9) I undertook the design of a continuous 
fluorescent kinetic TraI assay. This was ultimately unsuccessful, stymied by 
many of the same problems associated with previous TraI activity assays. 
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5.1 Results and Discussion 
5.1.1 Attempted continuous kinetic assays 
A continuous fluorescent assay was designed to measure the kinetics of 
TraI mediated ssDNA cleavage and relegation. Continuous kinetic assays for 
TraI relaxase activity were plagued by artifacts, many of which closely resembled 
the expected timecourse curves. The resemblance was great enough to drive a 
year-long effort to make the assay work. (Fig. 1) Protocol variations included 
different reaction buffers, temperatures, enzyme and substrate concentrations, 
and substrate sequences.  All substrates were tested to ensure that they were 
within desired melting temperature bounds, but the forward and reverse melting 
curves differed more and more markedly as the rate of temperature change 
increased. This hysteresis, time-dependant non-two-state behavior, may indicate 
either multiple folding states or simply slow melting. (Fig. 2) The time for 
maximum melting was on the order of seconds to minutes, such that the melting 
rate of the substrate appears to have prevented accurate kinetic measurements. 
The observed first order increase in fluorescence during kinetic time courses was 
likely do to slow equilibration, rather than to substrate cleavage, as confirmed 
later by negative controls. In future, continuous TraI kinetic assays should avoid 
reliance on hydrolysis for product formation and DNA hybridization for product 
detection. I have recommended that others in the lab try fluorescence anisotropy 
for relaxase kinetic measurements, relying on the change in oligonucleotide size 
for readout of cleavage and relegation.  
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5.2 Materials and Methods 
5.2.1 Oligonucleotide design 
All oligonucleotides were ordered from Integrated DNA Technologies 
(IDT). Substrate oligonucleotides were large loops (20-30 bases) with 
complementary termini (stemloops), 5’ end-labeled with a fluorescein derivative 
(6FAM) and 3’ end-labeled with a quencher (Iowa Black FQ). The internal loop 
sequence was based on the previously determined tightest binding F-plasmid 
oriT segment containing the TraI nick site (1). The termini were chosen from all 
possible complementary sequences of seven bases or less. This list was 
generated in Microsoft Excel and then all melting temperatures estimated with 
the various oligonucleotide software packages on the Rensselaer bioinformatics 
web server (10). Oligonucleotides were chosen for homodimer and internal pair 
melting temperatures <27 °C. Stem loop (5’ to 3’ terminal complementarity) 
melting temperatures were limited to >44 °C for intact oligonucleotide and <27 °C 
for cleaved or nicked oligonucleotides (stem oligos). A subset of these were also 
chosen with stem melting temperatures >61 °C and an inverted repeat on the 5’ 
terminus capable of hairpin formation with melting temperatures between 47 and 
52 °C (snapstem oligos). 
 
5.2.2 Oligonucleotide substrate validation 
Selected oligonucleotides and their simulated (synthesized) cleavage 
products were melted in and re-annealed in a Fluorolog spectrometer and their 
fluorescein fluorescence measured. The three snapstem oligonucleotides 
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(TACGCCTTGGGTGT*GGTGCTTTTGGTGGTGGCGTA, 
ACGAGCTTGGGTGT*GGTGCTTTTGGTGGTGCTCGT, 
CGTAAGTTGGGTGT*GGTGCTTTTGGTGGTCTTACG; asterisk marks nick site) 
and five stem oligonucleotides 
(CGTAAGTTGGGTGT*GGTGCTTTTGGTGGTCTTACG, 
CGTAAGTTTGCGTGGGGTGT*GGTGCTTTCTTACG, 
CGTAAGTTTTCGTGGGGTGT*GGTGCTTTCTTACG, 
CCTGTGTTTTTTCGTGGGGTGT*GGTGCTTTTCAGG, 
CCGCCTTGTTTTTTCGTGGGGTGT*GGTGCTTGCGG) with experimental 
melting temperatures within the above bounds were used in kinetic assays.  
 
5.2.3 Attempted Kinetic Assays 
Assay buffers were used as previously described (9). Briefly, kinetic 
assays were performed in a reaction buffer of 150 mM NaCl, 50 mM Tris-HCl pH 
7.5, 6 mM MgCl2 and 20% glycerol. Substrate oligonucleotide concentrations 
varied from 100-3600 nM. TraI relaxase domain (N300) concentrations varied 
from 0.5-10 nM. Reaction components (sans enzyme) were mixed at 37 °C. Pre-
reaction fluorescence readings were taken to represent 0 time. Reactions were 
initiated by protein addition and rapid tituration, and immediately (in <10 s) read 
by in a BMG Pherastar microwell plate spectrophotometer (plate reader). 
Reactions were followed until apparent equilibria were reached. 
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5.2.4 Data Analysis 
Nonlinear regression was used to analyze timcourses. Fluorescence 
timecourse data was fitted to first order exponentials. The regression parameters 
were then used to determine the initial reaction rates. Initial rates were plotted 
versus substrate concentration to construct apparent Michaelis-Menton velocity 
curves. These were then fitted with the simple Michaelis-Menton equation and 
subjected to Cornish-Bowden/Eisenthal direct linear plot analyses (11-13), both 
in order to determine apparent maximum reaction velocities (Vmax.app) and 
Michalis constants (Km.app). 
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5.3 Figure Legends 
Figure 1.  Probable equilibration artifact. 
F TraI DNA “cleavage” curve displaying an increase in fluorescence originally 
attributed to active ssDNA cleavage. This curve fit well to a first order exponential 
rise to maximum, as expected for simple Michaelis-Menton enzyme kinetics, and 
was used to get the first estimated TraI cleavage rate. Unfortunately, curves such 
as this were eventually shown to be artifactual, likely due to an equilibration 
effect after addition of protein to the reaction mixture. 
 
Figure 2.  Hysteretic melting curves. 
DNA melting (F) and refolding (R) for an example hairpin substrate 
oligonucleotide (designated oligo 7). The gap between the melting curves is due 
to hysteresis, i.e. in this case, slow or multi-state folding. This likely accounts for 
both the appearance of the curve in Figure 1, and the lack of real kinetic data. 
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Figure 5-1 Probable equilibration artifact 
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Figure 5-2 Hysteretic melting curves 
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6 Appendix 2: Progress Toward Further F Plasmid 
Protein Structures 
6.1 TraI constructs 
3D-PSSM tertiary structure prediction was used to analyze all F TraI 
regions. The known relaxase and helicase regions were correctly identified as 
such, and a novel domain was predicted, from residues 300-590, with homology 
to Ffh and FtsY bacterial GTPase domains (1). These predictions were confirmed 
to within 95% confidence with the Tertiary Structure Prediction Metaserver, using 
the 3D-Jury method for correlation results from the best benchmarked tertiary 
structure prediction services (2, 3). We used limited proteolysis on full length TraI 
to determine the boundaries of globular domains. Mass spectrometric analysis of 
trypsin digest fragments was inconclusive, but did yield enough information to 
infer domain boundary through assumption of parsimony. Five globular domains 
were indicated, corresponding to the protease resistant relaxase fragment 
(residues ~1-235), two novel domains of unknown character (~235-600, roughly 
corresponding to the putative GTPase, and ~600-900), and two subdomains of 
the helicase region (~900-1100 and ~1100-1500), in addition to many smaller 
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fragments in the carboxy-terminal 250 residues. Tertiary structure prediction 
failed for the third globular domain and the C-terminus. TraI constructs 309-590 
(putative GTPase) and 1-590 (N590) were expressed with the Impact expression 
system, purified and crystallized. Irreproducible crystal hits were observed for 
both constructs, but crystallization attempts were abandoned as priorities shifted 
to the relaxase and helicase domains. 309-590 crystals were GDP dependant. 
Limited proteolysis of the putative GTPase was performed in the presence and 
absence of GDP. The proteolysis footprint changed dramatically. The Matson lab 
showed that the putative GTPase will selectively bind GTP over ATP, but found 
no evidence for nucleotide triphosphate hydrolysis in any case. Fluorescence 
anisotropy-based DNA binding assays found evidence for cooperative DNA 
binding by both novel domains, the helicase domain, the relaxase domain, and at 
least a portion of the C-terminal regions. These data were collected in our lab by 
Jenny Xue, under Dr. Laura Guogas, and will be included in a manuscript by 
those investigators. The last hundred or so C-terminal residues were predicted to 
adopt a coiled-coil structure by Coils  (4), Paircoil2 (5), and Multicoil (6). Since 
the Matson lab discovered an interaction between the C-terminal and TraM (7, 
8), Dr. Gougas has solved the structure of the first, most conserved, C-terminal 
domain, sans the predicted coiled coil. The TraI regions between the relaxase 
and the helicase and the far C-terminus still lack structural characterization. 
6.2 The F relaxosome 
Interactions have been postulated between the TraI C-terminal region and 
TraM (based upon gel shifts and TraM dependent nicking stimulation (7)), 
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between the putative TraI GTPase region and TraD (in analogy with the Ffh-FtsY 
pair (9, 10)), between TraM and TraD (based on a variety of data in the pKM101, 
R1, and F systems (11-15)), and between various TraI domains (based on the 
DNA binding data from Xue and Guogas, above). The multitude of interactions 
makes it likely that the relaxosome may be a more compact entity that could be 
expected from its very high molecular weight and large number of subunits. If this 
is the case, then crystal structures of the relaxosome and/or of its various 
component complexes should be resolvable. The Matson lab had proven capable 
of reconstituting active relaxosomes in vitro, in low concentrations. The first step 
in structural characterization of the full relaxosome may be small angle x-ray 
scattering experiments using reconstituted relaxosomes in solution. Small angle 
scattering should reveal the shape of the overall envelope of the structure. 
Enough structural data and homology models exist for each component that the 
envelope shape may be sufficient for the modeling of the relaxosome, which 
could lead up to new or improved interaction hypotheses leading to the full high 
resolution crystal structure. The Redinbo and Matson labs have accomplished 
the over expression and crystallography-scale purification of each individual 
relaxosome component. I will begin these studies in the spring of 2008, thought 
they will most likely have to be completed by others after my tenure at UNC 
comes to a close. 
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7 Appendix 3: Progress Toward a Comprehensive Real-
Time Mating Assay 
7.1 Previous attempts 
Most current mating assays rely on endpoint analysis, as opposed to 
being continuous readouts. This makes it difficult to assay both inhibitor 
concentrations and exposure times, the two fundamental metrics of antibiotic and 
pharmaceutical efficacy. In 2005, de la Cruz et al. demonstrated a real-time 
mating assay using a fluorescent reporter (lux gene) inserted into an expression 
plasmid, downstream of a T7 promoter and an artificial R388 oriT sequence (1). 
When donor cells containing an oriT deficient R388 plasmid and the plasmid with 
the fluorescent protein gene were mated to a DE3 cell line, the fluorescent 
protein was expressed. The level of fluorescence at any time point was 
proportional to the number of transconjugation events. It was stated that this 
assay would allow a high-throughput screen of potential inhibitors. While clever, 
this assay relied on several assumptions, chief among them that donor and 
recipient concentrations remained unchanged for the duration of the experiment. 
This assumption places limitations on the viability of the assay for inhibitor 
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testing, namely that inhibitors that kill donor or recipient cells will be 
misrepresented. It could be argued that any initial high-throughput hit thus 
gleaned could be further characterized by more complete assays after the fact. 
This means that a real-time assay capable of complete characterization of all cell 
lines would present economies of scale and time. In addition, in the existing 
assay, the transferred plasmid is itself non-conjugative, which does not 
accurately model the exponential nature of plasmid propagation. Thus any 
replacement assay should place the transconjugant marker on the transferred 
plasmid itself. 
 
7.2 Three fluors and complete characterization 
We believe that the solution to complete characterization lies in the unique 
fluorescent marking of each cell line. This idea has gone through several 
incarnations, of which I will describe only the most recent. This involves three 
plasmids, each with a fluorescent marker unique to each cell line (donors, 
recipients, and transconjugants). 
 
The current incarnation is based on the pCU1 plasmid system. Rebekah 
Potts has inserted a Venus yellow fluorescent protein gene into the T7 operon of 
a pET28a plasmid. She used PCR to pull out the entire operon, destroy the lac 
operator, and add Spe1 restriction sites to either end. The pCU1 plasmid has a 
unique Spe1 site outside of any known operons. The T7-Venus operon will be 
inserted into purified pCU1. This pCU1 variant (transconjugant marker) will be 
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electroporated into the intended donor cell line, HB101. The resulting cells will be 
made chemically competent in preparation for transformation with a pET11c 
variant encoding a second fluorescent protein (mCFP; the donor marker) and a 
ampicillin resistance gene. This plasmid should have low levels of constitutive 
fluorescent protein expression inside donor cells, analogous to that seen with the 
pET11c plasmid in JS11 cells during previous transfer complementation 
experiments. The recipient cells will be standard BL21 (DE3) cells bearing a 
pET28a plasmid (kanamycin resistance) encoding a third fluorescent protein 
(mCherry). 
 
This assay will use a 96-well format and with three fluorescent readouts 
which can be read in a microtiter plate reader such as a BMG Pherastar. Donor 
cells will fluoresce cyan, recipients red, and transconjugants both red and yellow. 
Cell counts may be calculated from standard curves relating cell count to net 
fluorescence at each wavelength. Initial calibration of standard curves will utilize 
the antibiotic resistances unique to each cell line using either agar plates colon 
counts or the Most Probable Number method of cell counting using dilution 
turbidity. The ultimate goal would be to establish an optimal mixture of cells and 
media that could be frozen in 96-well plates, ready for use in mix-and-measure 
type high-throughput assays. 
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